CareTrust REIT, Inc. (NYSE: CTRE) — Buys Skilled Nursing at Nine, Priced at Four

Report date: 25 July 2026 · Reference price: $43.25 (close, 24 July 2026)

Sector: Real Estate — Health Care REITs (skilled nursing / seniors housing, triple-net). CIK 0001590717. This analysis takes no position and contains no price target outside the clearly-labeled opinion block below.

⚡ The Author’s Take

This is the author’s own independent opinion, offered as general information only — it is not investment advice, and it is not a recommendation to buy or sell any security. Do your own research. Everything that follows it (Sections 1–15) is deliberately position-free and contains no recommendation and no price target.

Verdict: HOLD if you own it — AVOID here for new money — accumulate on weakness into roughly $32–$37 (about 16–18x forward Normalized FAD of ~$2.00, or a ~5.3–5.9% implied cap rate on the real estate). At $43.25 the stock is 0.8% below its all-time high, at the 99.3rd percentile of its own ten-year price-to-book range, and priced at ~21.6x forward FAD against a seven-year realized FAD-per-share growth rate of 3.8%.

Tag: “A cost of capital is not a moat.”

The one finding I would put in front of a committee first. Normalised to revenue over seven years, CareTrust wrote off 0.70% of revenue in rent against Omega’s 5.38% — genuinely 7.7x better, and the best evidence for its tenant selection. But it took 10.28% of revenue in real-estate impairments against Omega’s 4.98% — 2.1x worse. Netted, total credit charges are 11.55% versus 13.52%: only 1.2x better, not the order of magnitude the reputation implies. The reason the gap is invisible is an accounting one: impairments are added back in FFO and AFFO; rent write-offs are not. CareTrust’s pristine reported metrics are partly a function of its credit losses taking the form the non-GAAP measures exclude. “It underwrites better” survives only as “it gets paid its rent” — not as “it avoids bad real estate.”

This is a genuinely good business and an unusually honest one. CareTrust’s asset-level cash return has held between 8.65% and 9.33% for seven straight years and is at a seven-year high — through a 3.1x expansion of invested capital, it has not bought growth by lowering its return bar. Its revenue quality is the cleanest in the net-lease universe (straight-line rent was literally zero from 2020 to 2024 because its escalators are CPI-linked variable payments, not fixed bumps); its AFFO definition deducts straight-line rent and strips fair-value marks; cumulative operating cash flow has actually exceeded cumulative Normalized FAD; recurring capex has consumed just 4.7% of AFFO; the balance sheet is 100% unsecured with nothing due before 2028 and honest leverage of 1.3–2.4x against a 4.0–5.0x target; and Moody’s made it investment grade in April 2026. Portfolio EBITDAR rent coverage of 2.25x is roughly 70% above the 1.32x that Welltower discloses on the post-acute book it is actively pruning. None of that is in dispute, and none of it should be discounted.

What I object to is the price, and specifically the circularity underneath it. CareTrust buys skilled-nursing real estate at ~8.9% stabilized yields; the market capitalizes the portfolio it already owns at roughly 4.3–4.8% — about half the private-market cap rate, and ~200bp tighter than Omega Healthcare, which owns substantially the same asset class. That gap is not an operating moat; it is the business model, and it runs in one direction only. Eighty-two percent of seven years of growth was funded with equity, because at a 4.6% forward FAD yield CareTrust’s stock is genuinely cheaper than its own investment-grade debt. The arithmetic works beautifully — while the multiple holds. Re-mark the equity to the 14.3x it averaged from 2019 through 2023 and the identical 8.9% acquisition produces a 204bp spread instead of 415bp. And we know what this machine delivers at a normal multiple, because we have four years of it: from FY2019 to FY2023, total Normalized FAD grew 4.4% a year and FAD per share grew 1.2% a year. The 10.6% per-share growth since is arithmetically inseparable from a 43% re-rating of the equity. Today’s price requires roughly 4.9% perpetual per-share growth — above the seven-year realized rate — from an engine whose growth rate is a function of the very multiple in question. Meanwhile the dividend has compounded at 6.9% against 3.8% per-share FAD, ratcheting the payout ratio from 64% to ~81%.

Framing: a quality compounder at the wrong price, with a reflexive growth engine — not a falling knife, and explicitly not a momentum trade. The factor model is unambiguous: CareTrust’s Momentum loading is effectively zero and its Quality loading is negative in every nested model; ~58% of return variance is idiosyncratic. The advance is company-specific execution sitting on top of the single most in-favor industry factor in a 121-factor universe (REITs, 252-day z-score +3.84). Its factor-nearest neighbours are NNN, W. P. Carey, Healthcare Realty and Realty Income — while Omega, Sabra, NHI and LTC are absent entirely. The market is pricing the lease contract, not the Medicaid-reimbursed operating asset beneath it. And low beta is not defensiveness: this stock fell 67% in 2020, and its ten-year Sharpe ratio is 0.43.

Conviction: medium. What would flip me bullish: hard evidence that per-share FAD can compound at high single digits without multiple support — an inaugural investment-grade bond funding a large acquisition, or leverage moving toward 3–4x with the ~$1.0–1.9B of unused debt capacity actually deployed (worth roughly +7–13% to FAD/share at zero equity issuance). What would flip me bearish: a single-operator credit failure — the top ten tenants are ~69% of rent — or a loan-book loss crystallising against the ~$1.7bn book carried at management’s internal model. On reimbursement I have landed between two drafts: nursing facilities are carved out of the OBBBA provider-tax step-down, but "nursing facility services" is an expressly named in-scope category for the state-directed-payment phase-down that begins 1 January 2028 — and CMS-2449-P, published 22 May 2026, extends the cap to all state-directed payments from 2029. CareTrust’s own Q1 2026 10-K/10-Q regulatory section does not mention it. That is a dated 2028 risk, not a 2026 one, and at 2.52x coverage a 4% Medicaid cut still leaves ~2.05x against a ~1.1–1.2x danger threshold. The other trigger is substantiation of the June 2026 short-seller allegations against Ensign — 23% of contractual rent — which is currently 29% off its high while CareTrust sits at a record.

📈 Stock Price Action — Five-Year Event Map

CTRE has round-tripped from a ~$16 low in the 2022 rate shock to an all-time high of $43.60 (intraday, 22 July 2026), closing 24 July 2026 at $43.25 — 0.35% below its all-time closing high of $43.40 (21 July 2026) and near the top of a 52-week range of $30.51–$43.60. Over five years the stock has compounded a +127% total return (~+17.8%/yr) against a +78% price-only return — the ~49-point gap is the dividend, and that distinction matters for every comparison below. Two hundred fifty-one of the last 252 sessions closed above the 200-day EMA; the stock now sits ~16% above it.

Cycle narrative. (1) The 2021–22 decline was a duration repricing layered on genuine operator stress; CTRE bottomed at $16.21 on a total-return basis on 29 April 2022 — a −31% drawdown that took 17 months to recover. (2–3) Through late 2022 and early 2023 the stock traded the rate path in ±25% swings with no fundamental resolution. (4) From March 2023 the thesis changed: occupancy and Medicaid rates recovered, per-share FFO began compounding, and the acquisition machine scaled — the 9 February 2024 Q4-2023 print produced a +7.1% single-day move against +3.4% for the peer group, i.e. company-specific, not sector beta. (5) The October 2024 to February 2025 −23% leg was almost entirely the post-election long-rate back-up plus Medicaid-cut headlines; nothing in the portfolio broke. (6) The 15-month advance to May 2026 rests on hard, dated events — the Care REIT plc UK acquisition, two investment-grade upgrades, and roughly $2.5B of acquisitions across 2025–26 — punctuated by a sector-wide selloff on 20 March 2026 in which CTRE fell 8.0% against −4.3% for Omega and −2.7% for Realty Income. (7) The May–June 2026 −14% leg is textbook equity-issuance mechanics: management priced 14.4M shares forward two days off the high. (8) The move back to the all-time high carries no company news at all — it is rate relief and REIT-factor flow, and the reader should hold that fact next to the valuation section below.

1. Executive Summary

CareTrust REIT is a 43-employee, San Clemente/Dana Point–based triple-net landlord to skilled-nursing facilities (SNFs), seniors housing and — since May 2025 — UK care homes. It was spun out of The Ensign Group in June 2014 and has grown gross invested capital from $1.73B (FY2019) to ~$5.5B (Q1 2026), a 20.4% compound rate, while total revenue compounded 19.5% to $476M in FY2025 and ~$523M on a trailing basis. Management guides FY2026 Normalized FFO and FAD of ~$2.00–2.04 and $1.98–2.02 per share respectively, up ~14.8% and ~13.6% at the midpoints, on 234M weighted-average diluted shares.

The business is genuinely well run, and the accounting is genuinely clean. Five findings deserve explicit credit. First, the asset-level cash return on gross invested capital has held in a narrow 8.65%–9.33% band for seven consecutive years and is at a seven-year high in FY2025 — through a 3.1x expansion of the balance sheet. There is no evidence of reaching for assets. Second, revenue quality is the best in the net-lease universe: straight-line rent was effectively zero from FY2020 through FY2024, because CareTrust’s US leases carry CPI/RPI-linked escalators that are variable payments under ASC 842 rather than fixed bumps that must be straight-lined. Third, Normalized FAD deducts straight-line rent and strips the fair-value marks on the loan book — proper discipline, and better than many peers; cumulative operating cash flow of $1,366M has actually exceeded cumulative Normalized FAD of $1,330M over seven years, so AFFO does not run ahead of cash. Fourth, recurring capex has consumed only 4.7% of cumulative AFFO, validating the triple-net claim. Fifth, the balance sheet is 100% unsecured, fully fixed or hedged at a 4.294% weighted-average rate, has no maturity before 2028, and carries honest net-debt/EBITDA of 1.3–2.4x against a stated 4.0–5.0x target; Moody’s upgraded the issuer to Baa3 on 27 April 2026, giving a second investment-grade rating. Portfolio EBITDAR rent coverage of 2.25x (EBITDARM 2.79x) compares with the ~1.32x Welltower discloses on the post-acute book it is actively selling. Internal control has been effective in every year reviewed, with no restatement, no material weakness and no auditor change; Deloitte has served since 2019.

The problem is the price, and the circularity beneath it. CareTrust buys SNF real estate at ~8.9% stabilized yields. The market capitalizes the portfolio it already owns at an implied ~4.3%–4.8% cap rate — roughly half the private-market cap rate at which it transacts, and some 200bp tighter than Omega Healthcare, which owns substantially the same assets. That gap is not an operating advantage; it is the business model. At a 4.62% forward FAD yield, CareTrust’s equity is cheaper than its own investment-grade debt, which is precisely why 81.9% of the new capital raised between FY2019 and FY2025 was common equity and only 7.9% was net new debt. Issuing stock to buy at 8.9% is rational arbitrage — while the multiple holds.

The per-share record is the evidence that matters. Over FY2019–FY2025, total Normalized FAD compounded at 18.2% a year and diluted shares at 14.0%; Normalized FAD per share compounded at 3.8% — 21% of the dollar growth rate. On the cleaner FY2021–FY2025 window it is starker: total FAD +23.9% a year, per share +2.6%, and FY2023 FAD/share of $1.48 sat below FY2021’s $1.59 on a materially larger portfolio. Splitting the record by valuation regime is decisive: from FY2019 to FY2023, when the stock averaged 14.3x FAD, this identical machine delivered 1.2% annual per-share growth. From FY2023 to FY2026E, as the multiple re-rated from 15.1x to 21.6x, it delivered 10.6%. The growth rate and the multiple are not independent variables. Over the same span the dividend compounded at 6.9% — roughly 1.8x the per-share FAD rate — pushing the FAD payout ratio from 63.8% to ~78–81%.

Three further qualifications belong in the summary. (i) CareTrust is now a healthcare lender as much as a landlord: a ~$1.0B credit book of mortgage, mezzanine and preferred-equity investments generated ~26% of FY2025 Normalized FAD, and another ~4% was interest on idle cash and acquisition escrow — so roughly 30% of Normalized FAD is not rent. That book has stopped growing (Q1 2026 interest income was flat year-over-year while rental income grew 59%) and FY2026 guidance calls for interest income down 7–9% on $145M of assumed loan repayments. Capitalizing lumpy, mark-to-model loan interest at 21.6x implies roughly 2.5x book on senior and mezzanine SNF paper — a ~$1.4–1.6B mark-up, about $6–7 per share. (ii) Tenant credit is real and only partly observable: ~75% of contractual rent comes from operators with no public financials, and the 10-K states plainly that CareTrust has “not verified this information through an independent investigation or otherwise.” Ensign remains 23% of contractual rent — and Ensign is currently 29% below its March 2026 high following short-seller allegations of a “deliberate understaffing scheme,” unadjudicated as of this writing. (iii) Insiders have made zero open-market purchases in five years while the share count rose ~145%; the only cash sale on record was the departing CFO’s, five weeks before an equity offering.

Not a fraud, not a melting ice cube, and not obviously cheap. The reimbursement backdrop is currently supportive: the CMS minimum-staffing mandate was vacated in April 2025 and legislatively blocked into the early 2030s, and the FY2027 SNF Medicare rule proposes a +2.4% net market-basket increase. The Medicaid risk from the July 2025 budget law is smaller than the headlines imply, and this is a correction from our own first read: nursing facilities were expressly carved out of the expansion-state provider-fee step-down (CMS’s proposed rule of 23 July 2026 states the phase-down “is not applicable to … the nursing facility or ICF/IID permissible classes”), nursing facilities are only ~2.3% of state-directed-payment dollars, and the work requirements exempt nursing-facility residents. At 2.52x stabilized coverage, a 4% Medicaid rate cut still leaves ~2.05x against a ~1.1–1.2x threshold at which rent is genuinely at risk. A purely reimbursement-driven bear case does not work here. What does work is single-operator credit — the top ten tenants are ~69% of rent — and the loan book. What the price embeds is not heroic deal volume — roughly $300M of annual deployment would clear the bar, against $1.8B actually deployed in FY2025 — but the continued absence of credit loss and the persistence of a multiple at the 99th percentile of its own history. On the first, CareTrust’s own record in FY2022–FY2023 (collections of 95.5% and 97.7%, and $78.5M of combined impairments across FY2023–FY2024) shows the term can go negative. On the second, no company controls its own multiple.

2. Business Overview

2.1 What CareTrust owns and how it earns

CareTrust is a self-managed REIT that acquires healthcare real estate and leases it, almost entirely on a triple-net basis, to third-party operators. Under a triple-net lease the tenant bears taxes, insurance, maintenance and capital upkeep; the landlord collects a contractual rent and, in CareTrust’s case, an annual escalator. The economic consequence is a very high reported margin — G&A was 11.0% of revenue in FY2025 and the platform runs on 43 people — and an earnings stream whose principal risk is not property operations but tenant solvency and the reimbursement system that funds it.

At 31 December 2025 the portfolio comprised 366 skilled-nursing facilities and 208 seniors-housing properties (of which 131 were UK care homes), totalling 37,628 beds and units across 407 properties, rising to 417 properties and 38,512 beds/units by Q1 2026. A crucial distinction that the headline counts obscure: only 236 of the 366 SNFs and 171 of the 208 seniors-housing properties are actually owned. The remainder are exposures created through mortgage, mezzanine and preferred-equity lending rather than fee-simple ownership. Investors reading a 574-property headline are reading a number that includes roughly 167 properties CareTrust does not own.

Revenue divides into four streams (FY2025, $000s):

The composition shift is the single most under-appreciated fact about the business. Interest income was 2.7% of revenue in FY2019, 8.8% in FY2023 and 22.5% in FY2025. CareTrust has become a hybrid: a landlord with a substantial specialty-finance arm attached.

Within rental income, the cash-versus-accrual split is unusually clean:

Non-cash rent was 4.2% of FY2025 rental income against ~1.3% in FY2024 — and the entire FY2025 straight-line figure arrived with the UK acquisition, whose leases carry fixed escalators. US leases use CPI/RPI-linked escalators floored at zero and subject to caps, which under ASC 842 are variable lease payments recognised as incurred. Management’s FY2026 guidance assumes a 2.5% realised escalator.

2.2 Lease structure and the master-lease architecture

Leases are long-dated, structured as master leases covering multiple facilities, and cross-defaulted — a tenant cannot cherry-pick profitable buildings and hand back the rest. This is the same architecture that VICI Properties uses in gaming, and it is the strongest structural feature of the model: it converts a portfolio of individually marginal buildings into a single all-or-none obligation. The Ensign relationship illustrates the form: at 31 December 2025 Ensign occupied 113 properties with 12,218 beds under eight “Original Leases” ($79.6M, 19% of rent) plus three “New Leases,” totalling $92.1M or 23% of annualised contractual rental income, with CPI escalators subject to caps, no purchase options, and asymmetric cross-default provisions favouring the landlord.

Two features cut the other way. Ensign and Pennant leases give the tenant the right to require CareTrust to fund capital expenditure up to 20% of the initial investment — a call on the landlord’s balance sheet, not a landlord option. And there is a material disclosure gap: the FY2025 10-K contains no lessor future-minimum-rent schedule, no lease-expiration table and no weighted-average remaining lease term, and quantifies neither security deposits nor the tenant letters of credit it says it holds. For a landlord with 23% of rent from one tenant and a portfolio of credit-sensitive operators, the absence of any quantified credit-support disclosure is a real hole.

2.3 The three “growth engines,” honestly sized

Management describes three engines. They are of very different quality and maturity.

US skilled nursing and seniors housing triple-net is the core and remains so — $705M of the ~$1.1B closed year-to-date 2026. Stated stabilized yields have run “with a 9 handle,” though the CIO conceded on the Q1 2026 call that on larger portfolios “we have had to … go below a 9% yield on the lease to get the deal,” and that a “bread-and-butter sale-leaseback at a 9.5% yield with no creativity needed” no longer exists.

UK care homes, acquired via the Care REIT plc scheme announced 11 March 2025 (108p cash, ~$817M headline) and completed 8 May 2025 for $595.4M of equity plus $245.1M of assumed net debt, ~$840.5M all-in, added 131 properties and a London team. Coverage is reported at 1.75–1.8x EBITDAR and above 2.0x on an EBITDA basis — high for what are economically seniors-housing assets. Yields are “mid-8s.” The UK went from zero to 17% of Q1 2026 revenue in four quarters, co-equal with California. Two caveats: the acquisition was accounted for as an asset acquisition rather than a business combination, which permitted ~$20.7M of transaction costs to be capitalised rather than expensed and left zero goodwill on the balance sheet; and Deloitte excluded Care REIT from the FY2025 internal-control audit scope — 18.5% of total assets and 11.5% of revenues — under the permitted first-year carve-out. FY2026 is the first year that fifth of the balance sheet is inside the control opinion.

SHOP (seniors housing operating portfolio, i.e. RIDEA structures where CareTrust takes operating rather than rental economics) launched in Q4 2025 with three Texas communities and stood at four communities by May 2026. This is the smallest engine and the hardest won. Management targets low-double-digit IRRs and 7%+ year-one yields — below the SNF yield — and the CEO volunteered that “one of the surprises has been to see how aggressive some of our competitors’ underwriting has been. Even for deals that … we really like and stretch for, we sometimes get beat by folks that do not have the cost of capital that we do.” SHOP cap rates compressed “50 bps or more” in six months, with class-A primary assets at “a five handle.”

A fourth engine exists but is not described as one: the credit book. At 31 December 2025 it totalled $1,001.7M of principal ($1,014.7M carrying) across mortgage loans ($719.3M at 8.8%), mezzanine loans ($57.0M at 12.1%), preferred equity ($83.8M at 11.5%), a financing receivable from a failed sale-leaseback ($91.3M at 12.0%), a UK mortgage ($20.9M at 6.1%) and other loans ($29.5M at 8.4%, net of a $7.0M credit loss). Management frames lending as strictly instrumental — “we will only do loans if they include real estate acquisitions or we are confident that they will lead to real estate acquisitions” — and the record supports that: the Q2 2026 California transaction paired a $380.3M sale-leaseback of 15 SNFs with ~$163M of new loans to the seller’s affiliates. But instrumental or not, it is credit risk on a REIT balance sheet, elected at fair value under ASC 825 and valued by “an internal valuation model” rather than carried at amortised cost with a CECL reserve.

Verdict. CareTrust is a well-constructed, cheaply-operated rent-collection and lending platform on a supply-constrained asset class, with a genuinely strong master-lease architecture and unusually clean cash-rent recognition. It is also less of a pure landlord than it appears — roughly a fifth of revenue and nearly a third of AFFO is interest, and roughly 167 of its headline properties are lending exposures rather than owned buildings. The three-engine framing is aspirational: engine one is the business, engine two is one year old and 17% of revenue with a control-scope carve-out, engine three is four buildings, and the unnamed fourth engine is in run-off.

3. Industry Dynamics

3.1 The structure: a supply-constrained asset class funded by a politically-determined payor

Skilled nursing in the United States is roughly 15,000 facilities, highly fragmented across regional chains, independents and non-profits, with a long tail of sub-scale and financially stressed operators. Two forces define its economics, and they point in opposite directions.

Supply is genuinely, structurally constrained — this is the strongest element of the bull case and it deserves to be stated without hedging. New SNF construction is essentially uneconomic: Medicaid, which funds roughly half of SNF patient days, reimburses at or below cost, so a developer cannot underwrite a new building against the prevailing rate. On top of that, certificate-of-need (CON) regulation in many states caps bed licences outright, creating what amounts to a government-granted supply quota and a tradeable “bed-licence bank.” The result is that SNF beds are in net-negative supply — capacity is shrinking through closures faster than it is added. Seniors housing tells the same story from a different direction: NIC primary-market inventory growth was ~0.4% year-over-year in Q1 2026, the lowest on record back to 2006; construction starts are near their weakest since 2009; the development cycle runs ~29 months, so anything breaking ground today opens in 2028; and industry occupancy of ~89.5% reflects a nineteenth consecutive quarter of absorption exceeding inventory growth. Ventas management notes only ~1,500 new seniors-housing units started in Q1 2026 and that rents would need to be 20–40% higher for new development to pencil.

Demand is arithmetically certain in direction, and roughly half as strong as the sell side describes in magnitude. The US 80+ population runs from ~15.2M in 2026 to ~18.8M in 2030 (+23.5%) and ~26.8M by 2040 (+76%), an 80+ compound rate of ~5.4% a year to 2030 and an 85+ rate of ~4.2%. The oldest baby-boomers turn 80 in 2026, so the inflection is happening now rather than in a forecast.

But the bull case habitually skips the offset: the institutionalisation rate has been falling ~2.32% a year (residents per person aged 85+ went 0.2502 in 2010 to 0.1718 in 2026), and beds per 1,000 aged 85+ have gone 330 (2005) → 301 (2010) → 216 (2026). MedPAC’s data is blunter still — between 2010 and 2019, before COVID, covered admissions per fee-for-service beneficiary fell 18.5% and covered days 25.2%. Netting demographics against per-capita drift and supply attrition:

The thesis survives, at roughly half its headline strength. Two further brakes deserve naming: the occupancy recovery is ~85% complete (NIC: 88.8% pre-COVID → 74.6% trough → 86.7% in Q1 2026, leaving ~2.1 points), and roughly 130,000 certified beds — 8.3% of the stock — are mothballed (79.5% occupancy on certified beds versus 86.7% on available), returnable without a single new building now that industry headcount has fully recovered to its February 2020 level. NIC estimates the US needs ~549,000 additional units by 2028 and ~806,000 by 2030 merely to hold penetration constant, against deliveries running at roughly one-third of requirement. The demand-supply spread most plausibly peaks around 2027–28.

Against that, the revenue line is set by government, not by the market. Nursing care facilities and continuing-care retirement communities derive roughly 45% of revenue from federal sources, 13% from state and local, and 42% from private — making them the second-most government-funded provider category in American healthcare and, critically, carrying the second-highest state-and-local dependence of any category. Ensign’s own disclosure puts Medicaid at ~46.6% and Medicare at ~24.7% of skilled-services revenue. The economically decisive variable is skilled mix: Medicare Part A and managed-care patients are short-stay, higher-acuity and pay multiples of the Medicaid custodial per-diem, so a facility’s margin is driven less by occupancy than by the composition of that occupancy.

This is where the transmission mechanism to a landlord becomes clear. In the standard framing of healthcare economics, cost pressure flows strictly downstream: payors squeeze plans, plans squeeze providers, and providers respond by finding “degrees of freedom” in their cost structures. A triple-net landlord sits one tier below anything that framework models — and rent is one of those degrees of freedom. Labour is ~59% of a facility’s cost stack and is largely non-discretionary; rent is a fixed obligation that becomes negotiable precisely when coverage compresses. CareTrust’s rent is senior to the operator’s profit but junior to its wage bill.

3.2 The reimbursement calendar — real risk, but back-end loaded

The current reimbursement environment is supportive, and any honest assessment has to concede three specific pieces of good news.

First, the CMS federal minimum-staffing mandate is dead for the foreseeable future. The 2024 rule (24/7 RN coverage plus minimum nurse-hours per resident) was the single largest cost threat to SNF operators. It was vacated by a federal court in April 2025 and further blocked by the 2025 budget law into the early 2030s. This is resolved, not pending, and it removed a genuine existential margin threat.

Second, Medicare rates are rising. The CMS proposed FY2027 SNF payment rule carries a +2.4% net market-basket increase. The structural offset is Medicare Advantage, which pays less than traditional fee-for-service and applies clinical-review and utilisation scrutiny — a slow, persistent compression of skilled-mix economics as MA penetration grows. But the headline federal rate direction is positive.

Third, operators are performing. Ensign posted record same-store occupancy of 84.3% in Q1 2026 with skilled-mix days +9.6% and Medicare revenue +9.8%, and raised FY2026 guidance to $7.48–7.62 of EPS (+15%). American Healthcare REIT’s Trilogy platform reported quality mix at 75.5% of revenue, SNF rate growth of +5% a year, MA rate growth +6.6%, occupancy 91.2%, and a SNF NOI margin above 20% for the first time since COVID.

The risk is Medicaid, and it is dated. The One Big Beautiful Bill Act, enacted 4 July 2025, restructured the state financing mechanics on which SNF supplemental payments depend. The relevant calendar:

A correction, and then a correction to the correction — both belong on the page. A first verification pass established that nursing facilities were deliberately carved out of the provider-tax step-down, and that finding holds. CMS’s proposed implementing rule of 23 July 2026 states the phase-down “is not applicable to … the nursing facility or ICF/IID permissible classes” — nursing-facility provider taxes are frozen at their 4 July 2025 rate but do not ratchet down from FY2028. Nursing facilities are also only ~2.3% of state-directed-payment dollars (~$2.1bn) against hospitals’ 84% (~$78.0bn), and the Medicaid work requirements exempt nursing-facility residents. The staffing mandate is dead three separate ways: a statutory moratorium to 2034, judicial vacatur in AHCA v. Kennedy (777 F. Supp. 3d 691), and repeal by CMS interim final rule effective 2 February 2026.

But a second pass found that the provider-tax carve-out is only one of four channels, and the most important one runs the other way. Under Section 71116, "nursing facility services" is an expressly NAMED in-scope category for the state-directed-payment (SDP) restrictions, and grandfathered SDPs phase down by 10 percentage points of the original dollar amount per year from 1 January 2028 (CBO scores this provision at −$149.4bn). CMS-2449-P (91 FR 30400), published 22 May 2026 with comments closing 21 July 2026 — four days before this article’s date — implements that phase-down for nursing facilities and goes beyond the statute, extending the Medicare-based payment cap to ALL state-directed payments, all services and all states from 1 January 2029. CMS’s own projection is $782.6bn of Medicaid spending reduction; KFF puts the federal share at ~$510bn, rising to ~$81bn a year by 2035. CareTrust’s Q1 2026 10-Q “Regulatory Updates” section discusses the FY2027 PPS rule, the PDPM request for information, the State Operations Manual and California SB 525 — and does not mention CMS-2449-P at all. That omission, on the single largest dated Medicaid item facing its tenants, is the cleanest bear catalyst in the file.

So the honest net position sits between our two drafts. The provider-tax leg of the bear case is genuinely weak for nursing facilities; the state-directed-payment leg is genuinely strong, explicitly names them, and starts in January 2028. Two things do soften it: the largest single OBBBA provision — work requirements, −$325.6bn — largely misses SNFs, since dual eligibles and mandatory-pathway enrollees are exempt and there is an explicit hardship exemption for any month in which a person receives “nursing facility services”; and the coverage buffer is real. At ~2.52x stabilized EBITDAR coverage, a 4% Medicaid rate cut on a ~50% Medicaid census is roughly a 2% revenue and 16–20% EBITDAR hit, taking coverage to ~2.05x against a ~1.1–1.2x level at which rent is genuinely at risk. The conclusion is not that reimbursement is a non-risk — it is that the risk is dated to FY2028–29 and sits outside both FY2026 guidance and today’s coverage print. Alongside it: single-operator credit concentration — the top ten tenants are ~69% of rent — and the loan book. Slower channels include Idaho’s 4% across-the-board cut (already in the 10-K), retroactive eligibility shortening from 90 to 60 days on 1 January 2027, and semi-annual redeterminations from 31 December 2026.

Two further observations discipline the bear case. First, the empirical record since enactment runs the other way. Universal Health Services’ disclosed net Medicaid supplemental benefit rose from $1,016M (2024) to $1,339M (2025) to ~$1,472M on a trailing basis — it went up in the twelve months after the law passed, because new state programmes kept being approved; UHS repeatedly escalated its own 2032 impact estimate for exactly that reason. Second, legislated out-year reductions in this sector have a long history of being deferred: as the standard framing puts it, such cuts “have always proven politically challenging and so often fail to happen.” Ensign management’s read — that the sector “came through pretty well,” that rates are “steady state” for 2026–27, and that the risk sits “beyond” that horizon — is consistent with the calendar above.

There is also a live risk to the supply side of the bull case that receives almost no attention: CON regimes are themselves a deregulation target. The DOJ and FTC have recommended that states “remove barriers to entry for providers such as certificate of need programs.” The government-granted supply cap that underwrites SNF scarcity is a policy choice, and policy choices reverse.

3.3 Where the industry sits in the capital cycle

The Marathon supply-side read is the right lens, and it produces a split verdict that is consistent across every healthcare-REIT analysis in our files: the sector is favourable on physical supply and late-stage on capital inflows.

Physical supply is as constrained as it has been in two decades. But capital is arriving in force. Rolling four-quarter transaction volume is ~$24bn, a decade high; 86% of surveyed institutional investors plan to add senior-housing exposure in 2026; and Kayne Anderson closed its largest-ever fund (>$5bn) targeting the space in May 2026. The predictable consequence is visible in every landlord’s disclosures: Welltower now underwrites 6.5–7% year-one yields; Ventas reports cap rates moving “from the 7s into the 6s”; American Healthcare REIT buys stabilized product “in the 7s” and notes 25–50bp of compression with “more players are entering.” CareTrust’s own experience matches — stated blended stabilized yields went from 9.8% (FY2023) to 9.7% (FY2024) to 8.6% (FY2025) and 8.9% year-to-date 2026, and its CIO conceded that a “9.5% yield with no creativity needed” is gone while SHOP cap rates compressed “50 bps or more” in six months.

Verdict: a structurally attractive asset class for the best operators, and a structurally mediocre one for landlords. For the operator, CON-protected supply plus a demographic wave plus consolidation of a distressed tail is a genuinely good hand — which is why Ensign earns a ~22% ROE. For the landlord, barriers to entry are close to nil: anyone with capital can buy a building and sign a lease, and the returns available are a spread, not a rent. The industry’s defining feature for a REIT is that its tenants’ revenue is set by legislatures and its own returns are set by the cost of capital of whoever is bidding. Physical scarcity is real and improving; capital scarcity — the thing that actually determines a landlord’s returns — is deteriorating.

4. Competitive Position

4.1 Naming the moat in Greenwald’s taxonomy — and mostly not finding one

Greenwald’s framework admits three genuine competitive advantages: supply/cost advantage, demand-side customer captivity, and economies of scale combined with captivity. Tested honestly against CareTrust:

Supply or cost advantage in the asset: FAILS. CareTrust has no privileged access to SNF real estate. It buys in the same auctions and off-market processes as Omega, Sabra, NHI, LTC, family offices and — increasingly — Ensign itself. Its cost of construction, its property taxes and its insurance are not differentiated. It owns nothing proprietary.

Customer captivity: PARTIAL, and stronger than the net-lease norm. The standard net-lease critique applies in part: a tenant signs a long lease because the location is mission-critical, not because CareTrust owns it — sell the building to NHI tomorrow and the tenant’s rent and switching costs are identical. But two features of healthcare net lease create captivity that generic net lease lacks. First, licensure: transferring a SNF operating licence to a new operator takes months of state approval, and CON restricts changes of ownership as well as bed counts. Second, master leases with cross-default and all-or-none renewal: the tenant cannot hand back its losing buildings and keep the winners. Together these are genuine constraints — and they are demonstrated, not theoretical, in that CareTrust collected 100% of contractual rent through 2020, 2021, 2025 and Q1 2026.

The critical qualification is that licensure traps the landlord as much as the tenant. A vacant SNF cannot be re-let quickly, cannot be repurposed cheaply, and is worth a fraction of its leased value. When a tenant fails, CareTrust’s option is not to evict and re-price but to negotiate, abate, or pay. The record shows exactly that: in August 2025 CareTrust paid $12.3M to terminate and assign leases on 11 Covenant Care properties — the landlord wrote the cheque. Ask “who is captive to whom” and the answer is: both, asymmetrically, and the landlord’s captivity is the one that shows up in cash.

Economies of scale plus captivity: FAILS on scale, PARTIAL on relationships. At ~$5.5B of invested capital CareTrust is a mid-sized landlord in a fragmented market — smaller than Omega ($17.7B EV) and vastly smaller than Welltower. There is no scale threshold in this business that confers pricing power. The 43-person platform is genuinely efficient, and marginal G&A on an incremental $1bn deal is near zero, but that is operating leverage, not a barrier to entry: Omega and Sabra enjoy the same arithmetic.

4.2 The three moat claims management actually makes, tested

Claim one: a superior cost of capital. This is real and it is measurable — and it is also the least durable thing in the file. At a 4.62% forward FAD yield CareTrust’s equity is cheaper than its own investment-grade debt, and cheaper than the equity of every SNF peer. But a cost-of-capital advantage that consists of a temporarily rich share price is reflexive, not structural: it is an output of investor sentiment being treated as an input to strategy. A moat that disappears exactly when you need it is not a moat. The falsification is empirical rather than theoretical: from FY2019 to FY2023, when CareTrust traded at an average 14.3x FAD, this identical platform with these identical relationships delivered 1.2% annual per-share FAD growth. And management itself supplied the decisive counter-evidence on the Q1 2026 call, describing SHOP: “we sometimes get beat by folks that do not have the cost of capital that we do.” If cheap capital does not win deals, it is not a competitive advantage — it is a subsidy on the ones you do win.

Claim two: proprietary operator relationships and off-market deal flow. Better supported. Skilled-nursing transactions are predominantly relationship-driven and off-market, and CareTrust’s deployment record — $233.8M (FY2023), $1,528.6M (FY2024), $1,764M (FY2025), ~$1,109M year-to-date 2026, ~$4.69bn cumulative — demonstrates real sourcing capability that peers have not matched at that pace. Management’s operating pedigree is genuine: the CEO is a former licensed nursing-home administrator, and the “by operators, for operators” positioning is not merely marketing. The lending programme functions as a deliberate deal-origination funnel (“we will only do loans if they include real estate acquisitions or we are confident that they will lead to real estate acquisitions”), and it demonstrably works — the Mid-Atlantic sale-leaseback and the $380.3M California transaction both originated that way.

Claim three: superior underwriting and operator selection. This is the claim that would constitute a durable advantage if true, and the evidence is genuinely mixed — considerably more mixed than the narrative.

Supporting it, with one important caveat first. CareTrust’s disclosed "0% of rent below 1.00x coverage" covers only 300 of its 588 properties, excluding 77 recent acquisitions and 40 transitioned facilities — so the reported pool is survivorship-selected, and the CEO’s own description of asset management is "de-risking it as we go." With that stated: portfolio EBITDAR rent coverage of 2.25x (EBITDARM 2.79x) is far above the ~1.32x Welltower discloses on the post-acute book it is actively selling and the ~1.23x on its seniors-housing triple-net book; UK coverage of 1.75–1.8x compares with the ~1.1x at which US triple-net seniors-housing deals historically transacted. CareTrust has avoided anything resembling Omega’s serial tenant blow-ups. The PACS Group episode is usually offered as a favourable test, and the outcome was favourable — but the sequence is the strongest single piece of anti-moat evidence in the file, and it deserves to be laid out in order. On 1 November 2024, three days before Hindenburg Research alleged that false claims had driven more than 100% of PACS’s operating and net income from 2020 to 2023, CareTrust added four skilled-nursing facilities to the PACS lease at +$5.0M a year, with $1.1M of rent deferred over 24 months. PACS then fell 28%, missed four filings, announced a restatement, lost its CFO and received an NYSE delinquency notice. On 1 December 2024 — after the report — CareTrust signed a new 11-facility, 15-year Tennessee master lease with PACS, acquired through a joint venture, with a year-one abatement. Then on 1 February 2025 — after the report, with PACS under both DOJ and SEC investigation — CareTrust contributed $19.7M to a joint venture that bought a Tennessee facility for $20.4M and added it to the PACS lease at +$2.0M a year. PACS was 15% of total rent at 31 December 2024. By FY2025 it fell below 10% — and the “Significant Master Leases — PACS” section was deleted from the 10-K. Management has never named PACS on any retrievable call.

PACS did survive, and CareTrust was paid: $1.42bn of Q1 2026 revenue, 0.1x net leverage, a $250M buyback authorised. But four DOJ threads and an SEC enforcement investigation remain open with no reserve taken (“cannot estimate”), and the honest reading of the episode is not “our underwriting protected us” — it is that CareTrust increased its exposure to a tenant by roughly $7M of annual rent across and after a fraud allegation, a restatement, a CFO resignation and two federal investigations, and the tenant’s alleged fraud simply did not impair its cash flow. Management has also begun publishing CMS star-rating comparisons suggesting its tenants outperform sector averages (self-selected sample, four-year-minimum tenure, not independently verified).

The decisive test, and it splits the claim in two. Normalising seven years of credit charges (FY2019–FY2025) to cumulative revenue for CareTrust and Omega:

“CareTrust underwrites better” survives only in its narrow form — CareTrust gets paid its rent. It does not survive as “CareTrust avoids bad real estate.” Its exit route is to sell the building and re-tenant quickly; Omega’s is to grind out a multi-year restructuring. And here is the mechanism that makes the difference invisible: impairments are added back in FFO and AFFO; rent write-offs are not. CareTrust’s reported per-share metrics are pristine precisely because its credit losses take the form the non-GAAP measures exclude. Deloitte’s FY2023 critical audit matter was, fittingly, “impairment of real estate held for sale.”

Also cutting against it: the realized capital record for the 2015–2021 acquisition vintages is poor. Cumulative real-estate impairments FY2019–FY2025 total $176.8M, plus ~$7.0M of loan credit-loss reserve — roughly $183.8M of realized capital destruction. The $157.6M concentrated in FY2022–FY2024 landed on a portfolio whose total assets were only ~$1.6–2.1bn, meaning something like 8–10% of the pre-2022 book was written off. Contractual rent collections were 94.0% for FY2022 (93.2% in January 2022) and 97.7% for FY2023 — and note that the FY2025 “99.7%” figure rests on a changed, more flattering basis (“exclusive of properties held-for-sale and sold”) versus FY2022–FY2024’s “excluding cash deposits.”

The re-tenanting history is also more extensive, and more expensive, than the narrative implies: 16 named credit events since 2017, with rent resets of −65% (Noble to Pennant), −54% (Hillstone to Embassy) and −25% (a Kansas pool to Ensign). One Ohio pool failed three consecutive times — Pristine, then Trio, then Hillstone. Even the Covenant Care outcome, which genuinely ended well (an 11-property, $13.0M/yr California tenant replaced at +$3.9M, +30%, on longer leases), required $12.3M of cash plus $6.8M of intangible acceleration — roughly 1.5x the annual uplift — and Ensign’s participation to solve. And the tenant-transition list is long and continuous: Noble Virginia (terminated March 2023), Premier Senior Living (September 2023), Hillstone (deferred then terminated December 2023), Ridgeline (terminated December 2024, re-tenanted to Jaybird with three to six months of abated rent, four communities subsequently sold), Eduro (partial termination 2024), Covenant Care (August 2025, $12.3M paid by CareTrust), and a further four-SNF operator termination in August 2025. FY2025’s $31.5M net gain on disposition is real but follows $157.6M of write-downs on the same asset class — selling at a gain off an impaired basis is not evidence of good underwriting — and CareTrust provided $36.0M of seller financing plus a $36.8M mortgage to a buyer, so it has not fully exited what it sold.

There is also an accountability gap that makes the central claim unauditable from outside. The FY2025 10-K and Q4 2025 release contain zero same-store disclosure, and CareTrust never reconciles a prior vintage’s asserted “estimated stabilized yield” to a realized yield. Growth is reported as absolute investment volume and blended announced yields. Investors are asked to accept 8.6–9.9% stabilized yields on faith, from a management team of which 40% of the annual bonus is paid on deployment volume.

4.3 The Ensign problem, restated

The relationship with the former parent is usually framed as a strength — a hand-picked, best-in-class anchor tenant with strong coverage. Three facts complicate that.

Ensign is now a competing landlord. Its “Standard Bearer” segment is a captive REIT with 173 properties (155 owned debt-free), $36.1M of Q1 2026 rental revenue at 2.7x coverage, leasing to 137 Ensign-affiliated operators and 37 unaffiliated third parties. Ensign’s stated acquisition priority is (1) own-and-operate, (2) long-term lease, (3) own-and-lease-to-third-party — i.e. leasing from a REIT is its second choice. Backed by 1.73x lease-adjusted net leverage and >$1bn of dry powder, CareTrust’s largest tenant now bids against it for the same assets and has a structural preference to own rather than rent. That is simultaneously concentration risk, acquisition competition, and a ceiling on renewal pricing power.

Concentration fell by addition, not reduction. Ensign went from 32% of contractual rent (FY2021) to 23% (FY2025) and from ~30% of Q1 2024 revenue to ~17% in Q1 2026 — but the absolute Ensign rent grew to $92.1M. The denominator did the work. Meanwhile the operators added to dilute that concentration are, by construction, smaller and less proven: ~75% of contractual rent now comes from operators with no public financials and no credit rating, and the 10-K states that CareTrust has “not verified this information through an independent investigation or otherwise.”

Ensign is currently under a credibility attack. Hunterbrook Media (8 June 2026) alleged a “deliberate understaffing scheme” and Muddy Waters published a short report on 11 June 2026. Ensign fell ~29% from its 2 March 2026 all-time high of $215.76 to $153.65 despite a Q1 beat and raised guidance, and added $60M to its buyback authorisation on 15 June. The allegations are unadjudicated. Their significance for CareTrust is that Medicaid-integrity and understaffing claims carry False Claims Act and regulatory tail risk that transmits to the landlord as tenant credit risk. The sharpest single cross-read available is that CareTrust’s equity sits at an all-time high and its richest-ever book multiple while its former parent, reference operator and largest tenant trades 29% below its high on a fraud-adjacent allegation.

4.4 Verdict

No durable competitive advantage in the Greenwald sense — but a genuinely capable operator of a structurally mediocre business model. Two formal tests confirm it. The market-share stability test fails decisively: CareTrust’s share of the five listed skilled-nursing landlords’ revenue went 8.2% (FY2020) to 15.5% (FY2025), +7.3 points in five years — Greenwald’s threshold for concluding that no barrier to entry exists is a 5-point shift over five to eight years. The ROIC test fails too, at 4.6–6.9% GAAP. And there are no scale economies to point to: CareTrust is smaller than Omega, and its G&A is 11% of revenue and rising (+59% year over year). It lands squarely in Greenwald’s residual category — good management, emulable, no barrier. The moat claims resolve as: no asset advantage; real but partial and two-sided customer captivity from licensure and master-lease cross-default; no scale advantage; genuine and demonstrated sourcing capability; better-than-peer coverage ratios but a realized impairment record that contradicts the “disciplined underwriter” framing for its older vintages; and a cost-of-capital edge that is reflexive by construction and cannot be relied on through a cycle. What CareTrust has is a spread, not a rent — and a spread earned in an industry with no barriers to entry for capital, at a moment when capital is flooding in. Being demonstrably better than Omega at tenant selection is worth something real. It is not worth a multiple normally reserved for private-pay compounders.

5. Growth History and Forward Opportunities

5.1 The growth record, in dollars and per share

The table is the argument. Total Normalized FAD compounded at 18.2% a year; Normalized FAD per share compounded at 3.8% — 21% of the dollar rate. Roughly four-fifths of six years of earnings growth was absorbed by share issuance. On the post-COVID window it is worse: FY2021 to FY2025 saw total FAD compound at 23.9% and FAD per share at 2.6%, with FY2023’s $1.48 and FY2024’s $1.54 both sitting below FY2021’s $1.59 on a far larger asset base.

Splitting the record by valuation regime is the decisive exhibit:

At a normal multiple, this platform — with the same people, the same relationships and the same asset class — produced 1.2% annual per-share growth for four years. The 10.6% since is coincident with, and arithmetically dependent on, a 43% re-rating of the equity. Management has been candid about the underlying issue. Asked directly on the Q3 2025 call whether SHOP existed because the triple-net book delivers only “low single-digit” organic growth, the CEO answered: “it really is 1A, 1B there. They’re both compelling reasons.”

5.2 Where the growth actually comes from

Internal growth is lower than the headline escalator, and this is a correction worth making precisely. The 2.5% CPI-linked escalator assumed in FY2026 guidance applies to rent only — and rent is just 72.6% of run-rate cash revenue. Interest income (26.7%) carries no escalator at all, and SHOP (0.7%) grows with rate and occupancy. Blended, run-rate revenue grows ~1.84% and internal FAD growth is ~2.06%, not 2.5% — before credit loss. The more CareTrust lends, the lower its organic growth rate becomes, which matters because roughly 65% of 2026 year-to-date deployment ($721M of $1,109M) — and ~80% of what closed between 1 April and 6 May 2026 ($691M of $864M) — went into loans and financing receivables rather than owned real estate. That is the whole of the organic engine. Everything above it must be purchased, which is why the deployment record matters:

Cumulative FY2023 to mid-2026: ~$4.69bn deployed. That is a genuinely impressive sourcing record for a 43-person firm, and it is the strongest operational fact in the file.

But note the direction of yields. Going-in yields fell from 9.14% (FY2024) to 8.10% (FY2025), and stated blended stabilized yields from 9.8% to 8.6%. Within FY2025, SNF triple-net went in at 8.76% while seniors housing went in at 7.65% — so the mix shift to seniors housing and the UK is dilutive to going-in yield by construction, not by accident. The UK went in at ~8.1% pre-tax and, after ~100bp of withholding leakage, mid-sevens after tax on the CIO’s own description — roughly 160bp below what CareTrust was earning on 2024 US deals and ~260bp below after tax. SHOP targets 7%+ year-one, the lowest of all.

5.3 The forward opportunity set, and its honest limits

The supply-side case is the real one, and it is strong. SNF beds have been in net-negative supply for years: Q1 2026 marked the first inventory addition since 2017, and development remains, in the trade’s own word, “frozen.” The average US nursing home is 40 to 50 years old. Construction costs of $314–499 per square foot imply something like $140,000–300,000 per bed before land, against a 2025 national transaction average of $105,600 per bed — SNFs trade at a wide discount to replacement cost, which is precisely why nobody builds them and why the supply cap is durable. One sharp caveat that cuts against CareTrust specifically: it does not buy at that national average. Its FY2025 skilled-nursing acquisitions priced at roughly $161,935 per bed (~$192,740 blended across asset types) — inside the range of new-construction cost. The industry-wide replacement-cost cushion is real; CareTrust has largely paid it away. Meanwhile SNF occupancy passed 87% in Q1 2026, the highest since 2016, and SNF annual rent growth exceeded 5%, the fastest since 2008. Against a US 80+ population going from ~14.7M to ~23M by 2035, this is a genuinely favourable multi-year setup for whoever owns the beds.

The competitive-side case is much weaker, and it is deteriorating. Three pieces of evidence, none of them from CareTrust’s critics:

• Sabra’s CEO, on the Q1 2026 call: “The private buyers that we are all up against are buying OpCo and PropCo, and they also are feeding ancillary businesses. So as a buyer of real estate, we just cannot compete with that.” A vertically integrated private operator capturing operating margin and ancillary revenue can rationally outbid a real-estate-only underwriter. Owner-operators were 75% of SNF buyers in H2 2024; REITs and real-estate funds together were ~21%.
• Strawberry Fields REIT’s CEO, on the same quarter’s call, naming CareTrust: “We had a deal that we signed up and CareTrust came and stole it from us … they offered like $25 million more than us, which is crazy because the other people had already accepted our offer.” He added: “Historically, we never ran up against them. In the last year or two … we lost one deal to Welltower and one deal to CareTrust. We are not changing our model to pay more.” Strawberry Fields — a disciplined “10-cap” buyer funding itself at ~6.85% in the Israeli bond market and trading at ~10.3x AFFO — closed zero acquisitions in Q1 2026. It is being priced out of its own asset class by buyers with cheaper equity.
• Institutional SNF portfolios are printing well inside CareTrust’s stated yields. Sabra sold three SNFs at a 6.8% lease yield and has ~$410M awarded at 6.8%; Omega sold 18 CommuniCare SNFs at ~7.7%; NHI agreed to sell 35 assets at ~7.1%; the portfolio Strawberry Fields lost traded at ~8.5%. Omega’s own executives explained why rivals accept less: even at a “mid-6s yield,” if occupancy keeps improving, “the operating leverage that exists within the business alone can move this into the high-single and low-double-digit yields over time.”

The uncomfortable synthesis is that CareTrust is simultaneously the beneficiary and the cause of yield compression in its own market. It outbid a competitor by $25M because its capital is cheaper — and each such win lowers the yield available to everyone, including itself.

Two further structural observations. First, one of the three named engines is in run-off. Interest income was flat year-over-year in Q1 2026 ($24.7M versus $25.0M) while rental income grew 59%, and FY2026 guidance calls for interest income of $97–99M, down 7–9% from $107.0M, on an assumed $145M of loan repayments — revised up from $42M in the February guide. The highest-yielding tranche is running off fastest: mezzanine principal fell 31% and its weighted-average rate from 12.8% to 12.1%. Second, each new vertical is lower-yielding and less proven than the last. UK care homes are a hybrid assisted-living asset at mid-8s pre-tax; SHOP is four buildings at 7%+ with operating risk and landlord capex; and both dilute the pristine revenue quality of the legacy book — the UK deal alone introduced straight-line rent where there had been none for five years ($8.8M in FY2025, guided to $15M in FY2026).

Verdict: high-quality sourcing, low-quality per-share growth. The deployment machine is real and demonstrably better than peers’. But it converts into per-share value only at a favourable cost of equity, and the 3.8% six-year per-share compounding rate — against 18.2% at the entity level — is the honest measure of what shareholders have received. The forward opportunity is genuine on supply and genuinely contested on price.

6. Financial Quality

6.1 A necessary correction before any multiple is quoted

Third-party aggregators classify CareTrust’s interest income as non-operating, which understates its revenue and EBITDA by roughly a fifth and inflates every derived multiple:

The filing governs. A screen showing CareTrust at 26x EBITDA is wrong by a third; the honest figure is ~19.6x. That still represents a substantial premium to Omega (15.7x), Sabra (16.1x) and LTC (15.6x), but it is a 25% premium, not a 65% one, and the memo’s conclusions rest on the corrected number.

6.2 What is genuinely high quality — stated without hedging

Revenue recognition is the cleanest in the net-lease universe. Straight-line rent was $77K, $32K, $17K, −$29K and −$28K in FY2020 through FY2024 — effectively zero — because CareTrust’s US leases carry CPI/RPI-linked escalators that are variable payments under ASC 842 rather than fixed bumps requiring straight-lining. Peers with fixed 2–3% escalators book years of non-cash rent; CareTrust books almost none. Receivables are trivially small ($10.4M at year-end 2025), consistent with the reported 100% cash collection.

The AFFO definition is mostly disciplined. Normalized FAD deducts straight-line rent (−$8.8M in FY2025; −$15M guided for FY2026), deducts non-cash financing-receivable revenue, deducts net above/below-market lease amortization, and — importantly — strips out the fair-value marks on the loan book (−$15.8M in FY2025, −$9.0M in FY2024). Excluding a mark-to-model gain from a headline earnings measure is the conservative choice and management took it.

AFFO does not run ahead of cash. Cumulative operating cash flow of $1,366.4M exceeded cumulative Normalized FAD of $1,329.7M across FY2019–FY2025, with CFO ≥ FAD in five of seven years. That is unusual and genuinely reassuring; most aggressive REIT AFFO definitions fail this test.

The triple-net capex claim holds. Cumulative capital expenditure FY2019–FY2025 was $61.9M — 4.7% of cumulative Normalized FAD — and committed capex at year-end 2025 was only $6.2M, of which $5.1M earns incremental rent. This is not where the aggression is.

The balance sheet is genuinely conservative. Total debt of $900M comprises $400M of 3.875% senior unsecured notes due June 2028 and a $500M unsecured term loan due May 2030 swapped to a 3.5% effective rate — 100% fixed or hedged at a 4.294% weighted average, 100% unsecured, ~100% unencumbered assets, nothing maturing before 2028. Interest coverage is 9.5x (FY2025) and 11.1x annualising Q1 2026. Moody’s assigned Baa3 in April 2026.

Internal control and audit quality are clean. ICFR was effective in every year FY2021–FY2025; no material weakness, no restatement, no non-reliance, no auditor change; Deloitte since 2019; zero NT filings and no Item 4.01 or 4.02 events across the five-year corpus.

6.3 What is lower quality, and by how much

The stock-compensation add-back. FAD adds back 100% of stock compensation — $6.8M plus a $3.5M “extraordinary incentive-plan” grant in FY2025, $10.2M or 2.8% of Normalized FAD ($0.05 per share), with $12M guided for FY2026. Adjusting for it, FY2025 FAD/share is $1.71 rather than $1.76 and FY2026E is $1.95 rather than $2.00. Deferred financing amortization ($4.1M) is also added back. Both are non-cash, but stock comp is a real transfer of value.

Management’s leverage figure is not comparable to anyone else’s. The disclosed 0.6x net debt to annualised normalized run-rate EBITDA embeds three adjustments: it treats $355.9M of equity not yet issued (unsettled ATM forwards) as a reduction of debt; it nets off restricted cash and acquisition escrow, not merely cash; and it annualises a pro-forma run-rate EBITDA that credits mid-quarter acquisitions with a full period ($499.7M versus $452.0M of actual trailing). Computed conventionally:

The honest range is 1.3x to 2.4x — still exceptionally low, and the conclusion (materially underlevered) is unchanged. But this article should not repeat 0.6x without naming the adjustments, and net debt to enterprise value is ~10.4% on the post-quarter figures rather than the disclosed 3.6%.

Roughly 30% of AFFO is not rent, and that share is falling. Interest income was 2.7% of revenue in FY2019, 8.8% in FY2023 and 22.5% in FY2025 ($107.0M of $476.4M). Loan interest alone was 25.6% of FY2025 Normalized FAD, with a further 4.1% from interest on idle cash and acquisition escrow — pure carry on undeployed capital that disappears as rates fall or cash is deployed. This is a specialty-finance business bolted onto a REIT, and it is contracting.

The credit book carries real, partly unreserved risk. At 31 December 2025 the book totalled $1,001.7M of principal — larger than the entire debt stack. It comprises mortgage loans ($719.3M at 8.8%), mezzanine ($57.0M at 12.1%, secured only by pledges of holding-company membership interests), preferred equity ($83.8M at 11.5%, structurally subordinate with no stated maturity), a $91.3M financing receivable at 12.0%, a UK mortgage and $29.5M of other loans. Nearly all of it is carried at fair value under the ASC 825 election, valued by “an internal valuation model” — so credit and rate deterioration flows through other income rather than a CECL provision. Losses are already present: a FY2024 provision of $4.9M representing a 100% write-off of one loan placed on non-accrual, and a $7.0M reserve against $29.5M of other loans — a 23.7% reserve on that bucket. Mezzanine fair value sits below principal.

Two structural features deserve emphasis. First, exposure is layered within single borrowers: CareTrust holds the entire $29.0M “B” tranche (9.69%), the $75.0M most-subordinate “C” tranche, and a $25.0M mezzanine loan against one Mid-Atlantic operator’s 18-SNF facility — $129M to one credit across three levels of the same capital structure — plus preferred equity in the holding companies of borrowers under its own $165M and $260M mortgages. Being both the senior lender and the preferred equity in the same deal makes the recovery analysis circular and removes the diversification the structure appears to provide. Second, there is a disclosed mechanism for converting a troubled loan into an acquisition. On a UK mortgage the 10-K states CareTrust “intends to exercise its option to accelerate the mortgage loan, acquire the underlying real estate … and enter into a new long-term lease.” That is a legitimate origination strategy; it is also exactly how a credit problem becomes an “investment” without a reported loss.

Impairments contradict the underwriting narrative for older vintages. Real-estate impairments totalled $176.8M FY2019–FY2025 — $16.7M, nil, nil, $79.1M, $36.3M, $42.2M and $2.5M — with the $157.6M concentrated in FY2022–FY2024 landing on a portfolio whose total assets were only ~$1.6–2.1bn. Roughly 8–10% of the pre-2022 book was written off. FY2025’s $31.5M net gain on disposition follows those write-downs on the same asset class, and CareTrust provided $36.0M of seller financing plus a $36.8M mortgage to a buyer, so it has not cleanly exited what it sold.

Two disclosure gaps are material. The straight-line rent receivable balance has not been separately disclosed since 2018; write-offs are charged directly against rental income rather than shown as a provision, so gross write-offs are unobservable — FY2025 revealed only a $3.9M rental-income reduction “related to certain tenants on a cash basis”, with the tenants unnamed, the count undisclosed and the affected rent unquantified. And CareTrust discloses no security-deposit balance anywhere in the FY2025 10-K and references tenant letters of credit without quantifying them. For a landlord with 23% of rent from one tenant and ~75% from unrated private operators, that is a real hole in the credit-protection picture. Off-balance-sheet items include earn-outs of up to $42.5M and the Ensign/Pennant option to compel CareTrust to fund capex up to 20% of initial investment.

6.4 Returns on capital, and the spread that matters

The asset-level cash return has held between 8.65% and 9.33% for seven years and is at a seven-year high — through a 3.1x expansion of invested capital. That is a genuinely creditable finding and it deserves to be stated plainly: management has not bought growth by lowering its return bar. (Normalized FFO over book equity fell from ~16% to ~10% only because book equity was marked up by stock issued at 1.9–2.6x book, not because assets deteriorated.)

The crux is the cost side:

The spread is real, but between half and two-thirds of it is the multiple, not the assets. CareTrust genuinely buys at ~8.9% against a ~9% asset-level cash return that has held for seven years. But the 415bp funding spread it is monetising exists only because the equity trades at 21.6x forward FAD, a 4.62% cash cost. Re-mark the equity to its own FY2019–FY2023 average and the identical 8.9% investment yields ~204bp. A REIT whose model depends on issuing stock at ~20x AFFO and 2.4x book has a cost of capital that is a function of its own multiple — a reflexive input, not an independent one. And Section 5.1 is the empirical proof: at 14.3x, this machine delivered 1.2% per-share growth a year.

Verdict: do the economics improve with scale? No — they hold flat at the asset level and dilute per share. Asset returns are stable-to-improving, revenue quality is excellent, the balance sheet is genuinely strong and the AFFO definition is broadly honest. But 81.9% of seven years of new capital was common equity, only 7.9% was net new debt, retained cash covered just 10.2%, and dividends consumed 70% of cumulative AFFO. The business cannot self-fund growth; equity issuance is the model rather than a choice — and the arithmetic only works while the equity is priced where it is.

7. Capital Allocation

7.1 The equity-issuance record, and the accretion test it passes

Cumulative FY2019–FY2025: ~$3.61bn gross. Shares outstanding went from 85.9M (December 2018) to 223.4M (February 2026) — +160%. ATM capacity ratcheted $500M → $750M → $1.0bn (February 2026), with $879M available at 31 March 2026.

The accretion test is the fairest way to judge this, and CareTrust passes it:

Every raise was struck at a FAD yield 270–420bp below what the proceeds bought, and every raise was priced at 1.9x–2.6x then-current book. Book value per share rose from $8.58 (December 2022) to $18.12 (December 2025), +111%, precisely because management never sold stock below book. This is not a company issuing at a 5% yield to buy at 5%. Credit is due, and the bear framing that ignores this is wrong.

Note also what widened the spread. It was not better buying — going-in yields fell from 9.14% (FY2024) to 8.10% (FY2025). It was the cost of equity dropping from 7.10% to 5.28% as the stock re-rated. The spread is a function of the multiple.

7.2 What the spread actually delivered

Against a 270–420bp spread on a 2.6x-larger equity base, one would expect powerful per-share compounding. What shareholders got was 3.75% annual Normalized FAD-per-share growth over six years, with FAD/share falling from $1.59 (2021) to $1.54 (2024) while $2.28bn of equity was raised and the share count grew 94%. Total Normalized FFO grew 2.83x on 2.19x the shares — roughly three-quarters of the earnings growth was simply more shares.

The leakage is identifiable: $176.8M of cumulative real-estate impairments, rent ramps and abatements that make going-in yields 50–100bp below the advertised “stabilized” figure, and negative carry on pre-funded equity (the CFO conceded in Q3 2025 that “the timing gap between funding and closings … represented a short-term headwind” while cutting FY2025 guidance).

The accountability gap is the most serious governance finding in the file. There is zero same-store disclosure in the FY2025 10-K or the Q4 2025 release, and CareTrust never reconciles a prior vintage’s asserted “estimated stabilized yield” to a realized yield. Growth is reported as absolute investment volume and blended announced yields. The model’s central promise is therefore unauditable from outside — which matters enormously given Section 7.5.

7.3 Care REIT plc — the best decision in the record

Two hypotheses about the UK deal — that it was diworsification and that it was a reach for yield — are both falsified by the evidence.

CareTrust bought a 20-year-WAULT, 2.2x-covered, inflation-collared portfolio at a discount to a freshly marked-up NAV, funded at 0.5x leverage. The published criticism came from the seller’s side: QuotedData wrote that “the almost 10% discount to NAV this deal values the company feels like too much value is being left on the table,” and the scheme’s General Meeting passed with only 84.76% against a 75% threshold, with 8 of 51 voting Court-Meeting holders against. This was an investment-trust-discount arbitrage executed well.

The offsetting facts are real but second-order: it is yield-dilutive (~160bp pre-tax, ~260bp after tax, versus US SNF); currency is deliberately unhedged at the asset level (no GBP debt, no cross-currency swaps, only ~£15.4M of forwards on intercompany interest, with a ±10% FX move worth ±$3.8M of net income) on a business that is now 17% of Q1 2026 revenue; there is no UK reportable segment; Deloitte excluded Care REIT from the FY2025 ICFR audit scope (18.5% of assets); the 10-K contains zero mentions of the April 2025 National Living Wage (+6.7%) and employer National Insurance increases that raised UK provider costs by roughly 10%; and the external manager CareTrust acquired for ~$6.8M had previously resolved a defaulted tenant (Silverline, 7 homes) by transferring the leases to Melrose Holdings, a company wholly owned by a managing partner of that same manager.

7.4 The loan book as a capital-allocation decision

CareTrust has used equity issued at a 5.3–5.7% FAD yield to fund ~$1.0bn of 8.4%–12.1% subordinated operator credit — a book now larger than its entire debt stack, generating 22.5% of revenue. Management’s framing is that lending is instrumental to real-estate origination, and the record supports that. But the risk profile is a finance company’s, and it is being valued at a REIT’s multiple: at 21.6x forward FAD, the ~26% of FAD that is loan interest is capitalised at roughly $2.6bn against a ~$1.05bn book — about 2.5x book on senior and mezzanine SNF paper that a specialty lender would carry near 1.0–1.2x. That mark-up is on the order of $1.4–1.6bn, or ~$6–7 per share (14–16% of the price). The multiple is an assumption; the direction is not.

7.5 Dividend, buybacks, and the two tells

The dividend has been raised every year and never cut: $0.90 (2019) → $1.34 (2025) → $1.56 annualised (2026, +16.4%). But it compounded at 6.85% against 3.75% for FAD/share, so roughly half the dividend growth came from expanding the payout ratio from 63.8% to ~78–81%, not from cash-flow growth. In FY2024, 25.8% of the taxable distribution was a return of capital “because our aggregate cash distributions exceeded our annual earnings and profits” — a quiet confirmation that earnings did not cover the payout that year.

CareTrust has never repurchased a single share and has never had a repurchase authorisation. Every issuer-purchase table in five years of 10-Ks and 10-Qs shows “—” shares and “$—” remaining; the only “purchases” are shares withheld for employee tax. In May 2022 the stock traded at $16.93 — a 9.3% FAD yield, below its 2020 level — and management issued $48.1M of equity at $20.00 and repurchased nothing. A team that maintains a $1.0bn ATM and has never created the reciprocal tool is saying it believes the shares are always worth issuing, including now at the 99.3rd percentile of their own historical price-to-book.

7.6 The proxy — the mechanism that explains the entire strategy

The 2025 annual cash-incentive plan, verbatim from the 2026 DEF 14A:

Capital Deployment is defined as “total value of new investments closed during the year, including acquisitions and strategic M&A transactions” — with no per-share, ROIC, spread or yield condition attached. FY2025 actuals: Normalized FFO/share of $1.7602 cleared the “High” hurdle by $0.0011, or 0.06%; deployment of $1,764M cleared “Super”; leverage of 0.89x cleared “High.” Final achievement: 300%. The CEO’s $2.5M target bonus paid $7,750,000; total FY2025 reported compensation was $10,002,522, and economic pay for the performance year was nearer $17.0M.

Three features deserve emphasis:

Sixty percent of the bonus is not a per-share metric, and both non-per-share metrics are maximised by issuing equity. Forty percent is raw deployment volume. Twenty percent is low leverage — paying maximum at ≤3.0x and only Threshold at 4.0x — which means running the balance sheet at the company’s own publicly stated 4.0x–5.0x target would score at or below threshold on a fifth of the bonus. Management is paid not to use the debt capacity it advertises to investors. That is the answer to the puzzle of why a REIT with ~$1.06bn of unused, cheap, fixed-rate capacity funded 82% of seven years of growth with equity.

The per-share hurdle was re-based downward three years running. The 2022 “High” hurdle was 7.3% below FY2021’s actual $1.49; the 2023 hurdle 7.8% below; the 2024 hurdle still 1.1% below FY2021’s level three years later. The 2024 proxy states the levels “were lower … to reflect expected lower revenue levels.” Management therefore collected High, Super and Extraordinary payouts in 2022, 2023 and 2024 while Normalized FFO per share went $1.49 → $1.49 → $1.41 → $1.4993 — flat for four years.

Volume is now hard-wired into equity compensation, and pay is benchmarked to market capitalisation. The 2025 Outperformance Grant triggers on “>$750M in capital deployment inclusive of a strategic M&A transaction” (CEO $3.0M) interpolating to $1.5M more at $1.5–2.5bn; the CEO earned $3,396,043, with relative TSR only a subsequent re-earn condition. A discretionary January 2025 award was justified in writing by “over $1.5 billion of capital deployed … while reaching a record low leverage ratio … of 0.40x.” And the compensation peer group is selected on “broadly comparable market capitalizations and asset bases, which the compensation committee views as better indicators of executive scope and responsibility than revenue” — with the CD&A’s own chart plotting CEO pay “alongside CareTrust’s market capitalization.” Issue equity → larger market cap → larger peer group → higher pay. Say-on-pay drew only ~79% support in 2025; the recorded shareholder objection was the special 2024 award, and the committee’s response was to make the volume award permanent and formulaic.

Ownership and insider behaviour corroborate. All eight officers and directors hold 1,484,199 shares — 0.665% of the company; the new CFO holds zero. Across the full five-year Form 4 corpus (87 filings) there are zero code-P open-market purchases, one discretionary sale (the retiring CFO, 35,000 shares at $29.80 = $1.04M on 4 September 2024, with no 10b5-1 footnote, five weeks before an offering priced at $32.00), 1.03M shares granted and $16.7M withheld for taxes. This same team did buy once — a coordinated cluster on 13 August 2015 at $10.50, when the CEO, CFO and two others put in ~$1.09M between them. Nothing above $19,155 since. Governance is otherwise sound in form: six directors, annually elected, no classified board, independent chair since 2022, no disclosed Item 404 related-party transactions — though the CEO is the founder’s brother-in-law, and the founder rejoined an expanded board effective January 2026.

7.7 Verdict

Above average in outcome, poorly governed in process. They got the important things right: every raise cleared its cost of capital by 270–420bp and was priced above book, lifting book value per share 111% in three years; leverage was held at 0.4–0.9x, earning investment-grade ratings and real optionality; Care REIT was a well-executed arbitrage bought at a discount to NAV; and the dividend has never been cut. That is a better record than the bear case allows.

But the delivered per-share compounding was 3.75% over six years while $176.8M — 8–10% of the pre-2022 book — was written off; there is no same-store or realised-yield disclosure to verify the core claim; ~$1.0bn of subordinated operator credit sits on the balance sheet with one 100% loss already taken and a 23.7% reserve on one bucket; and no buyback has ever been authorised, including at a 9.3% FAD yield. The incentive plan explains all of it. Nothing in the compensation design, the disclosure regime or the insider record would restrain this team from continuing to issue and deploy even if the spread narrowed to nothing — because 60% of the bonus does not depend on the spread at all.

8. Changes and Headwinds — Last Two Years

Transformative external growth. Deployment ran $1,528.6M (FY2024), $1,764M (FY2025) and ~$1,109M in the first four months of 2026 — ~$4.4bn in roughly thirty months against a starting invested capital base of ~$2.2bn. Property count went 224 (FY2023) → 258 → 407 → 417; beds and units 24,218 → 38,512.

International entry. The Care REIT plc acquisition (announced 11 March 2025, completed 8 May 2025, ~$840.5M all-in) added 131–137 UK care homes and a London team. The UK reached 17% of Q1 2026 revenue in four quarters, co-equal with California, with no separate reportable segment and no matched-currency debt.

A third business model. SHOP/RIDEA launched in Q4 2025 with three Texas communities (270 units) and reached four communities by May 2026. For the first time CareTrust bears operating and capital-expenditure risk rather than collecting contractual rent.

Balance-sheet and ratings progression. The revolver was doubled to $1.2bn (December 2024); a $500M term loan was added in June 2025 and swapped to a 3.5% effective rate; the Care REIT secured debt was repaid; Fitch assigned BBB− in May 2025 and Moody’s upgraded to Baa3 on 27 April 2026 at an indicated ~+130–140bp for ten-year paper. Two qualifications belong here: S&P’s corporate rating is still BB+, so this is not uniformly investment grade; the 3.875% coupon on the 2028 notes is a June 2021 artifact rather than evidence of current pricing power (Omega printed 5.200% in June 2025); and CareTrust has never tested the public investment-grade bond market — no bond has yet been issued. CareTrust reached Baa3 roughly seven months after Sabra.

Management turnover at the top of finance. Founder-era CFO Bill Wagner retired effective 31 December 2025, succeeded by Derek Bunker — who had been a paid consultant on the Care REIT transaction from January to June 2025 before appointment, and who came from Ensign and Pennant. Founder Greg Stapley, who left the board in July 2022, rejoined effective 1 January 2026 on a board expanded from five to six seats. CIO Mark Lamb resigned in November 2022, succeeded by James Callister.

Tenant churn has been continuous. Noble Virginia (terminated March 2023), Premier Senior Living (September 2023), Hillstone (deferred, then terminated December 2023), Ridgeline (terminated December 2024, re-tenanted to Jaybird with three to six months of abated rent, four communities later sold), Eduro (partial termination 2024), a Kansas SNF moved to Ensign, two Illinois assisted-living facilities, Covenant Care (August 2025, where CareTrust paid $12.3M to terminate and assign leases on 11 properties), and a further four-SNF termination in August 2025. FY2025 dispositions were 24 properties for $153.5M of net proceeds — including $36.0M of seller financing — against $122.0M of carrying value.

The reimbursement environment improved, then acquired a long-dated threat. The CMS minimum-staffing mandate was vacated in April 2025 and legislatively blocked into the early 2030s — removing the sector’s largest cost threat. The proposed FY2027 SNF Medicare rule carries +2.4%. Against that, the One Big Beautiful Bill Act (enacted 4 July 2025) freezes provider-fee safe harbours and steps expansion-state rates down 0.5% a year from FY2028 to FY2032, six-monthly redeterminations begin January 2027, and the CMS state-directed-payment cap bites around CY2028.

The single most important development is not CareTrust’s own. On 8 June 2026 Hunterbrook Media alleged a “deliberate understaffing scheme” at The Ensign Group, and Muddy Waters published a short report on 11 June. Ensign — CareTrust’s former parent, reference operator and 23%-of-rent largest tenant — fell ~29% from its 2 March 2026 all-time high of $215.76 to $153.65 despite a Q1 beat and raised guidance, and added $60M to its buyback. The allegations are unadjudicated. Separately, PACS Group — ~11% of Q1 2025 revenue — passed through a short-seller attack, delayed filings, a lender forbearance and a securities class action and recovered, reporting $1.42bn of Q1 2026 revenue and 0.1x net leverage; CareTrust had granted $1.1M of deferred rent inside a $5.0M rent increase and collected.

Verdict: the changes strengthen the entity and weaken the per-share story. CareTrust is larger, more diversified, better rated and more liquid than two years ago, and it resolved its largest tenant scare without loss. But it also added currency risk it chose not to hedge, an operating-risk business line, a fifth of its balance sheet outside the FY2025 control audit, a lower going-in yield mix, and a share count up ~60% — while its anchor tenant became a competing landlord under a fraud-adjacent allegation.

9. Risk Analysis

The two risks that matter are #1 and #3, and they are linked. A multiple compression alone slows growth; a credit event alone dents earnings. Together — a Medicaid-driven coverage decline that both cuts cash rent and re-rates the equity toward its asset-class peers — is the scenario that does real damage, and it is precisely the sequence Omega and Sabra lived through between 2017 and 2022.

10. Valuation Discussion

10.1 Where the stock trades

At $43.25 (24 July 2026) against FY2026 guidance of $2.00–2.04 Normalized FFO and $1.98–2.02 Normalized FAD per share. One share-count subtlety matters: guidance divides FAD by a 234M weighted-average count, but the market capitalises 250.6M shares fully settled (236.2M outstanding on the 15 May 2026 cover plus the 14.375M May forward, greenshoe exercised in full at a $40.225 initial forward price). On the fully-settled count FAD per share is $1.885 and the multiple is 22.9x, not 21.6x — and 250.6M is a floor, since $879M of ATM capacity remained and the Q2 10-Q is not yet filed:

The own-history percentiles are the cleanest single datum: price-to-book sits at the 99.3rd percentile of CareTrust’s own ~ten-year range — the richest ever — with price-to-sales at the 91.5th and a composite at the 82.3rd. (The 56th-percentile P/E should be discounted; GAAP EPS is distorted by depreciation and disposition gains for any REIT.)

10.2 The peer table — lead with the unlevered comparison

CareTrust’s 0.6x disclosed (1.3–2.4x honest) leverage is not comparable to Omega’s 3.5x or Sabra’s 5.0x on a per-share multiple, because leverage mechanically inflates per-share earnings. The unlevered comparison is the honest one.

The single most important observation in this article: CareTrust at 21.6x trades above every net-lease REIT in the table — the whole investment-grade net-lease complex sits between VICI at 10.9x and Agree Realty at 17.7x, and the entire SNF cohort runs from Strawberry Fields at 10.3x through Omega at 16.0x — and CareTrust sits instead among the private-pay seniors-housing operators (Ventas 25.6x, American Healthcare 26.0x) whose payor mix is ~96% private pay and who carry essentially no Medicaid rate risk. The factor model corroborates this independently: CareTrust’s factor-nearest neighbours are NNN, W. P. Carey, Healthcare Realty and Realty Income, while Omega, Sabra, NHI and LTC are absent from the similarity list entirely. The market has re-classified a Medicaid-reimbursed skilled-nursing landlord as an investment-grade private-pay duration asset.

Now the unlevered version. Stripping each company’s credit book to par and capitalising run-rate cash NOI:

The market capitalises CareTrust’s existing skilled-nursing portfolio at roughly half the cap rate at which CareTrust buys identical assets, and at roughly 40% of the broad-market survey cap rate for the same asset class. On a consistent same-date basis the gap to Omega is 164bp — +36% per dollar of rent. And there is no cohort-selection escape: the investment-grade net-lease median (~6.24%) and the SNF/seniors-housing median (~6.26%) are essentially identical, so CareTrust is ~164bp tighter than both. It is priced tighter than Realty Income (6.13%), NNN (6.37%), W. P. Carey (6.24%), Essential Properties (~6.15%) and even Agree Realty (~5.05%), the richest investment-grade net-lease compounder in the group. The only healthcare REIT priced tighter is American Healthcare REIT at ~4.14% — 79% RIDEA, with same-store NOI growing roughly ten times faster. CareTrust receives an operating-platform cap rate for a 2.5%-escalator triple-net portfolio. Note also that every peer is priced inside where it buys, but none by CareTrust’s margin: NNN buys at 7.5% against a 6.37% implied cap (−113bp); Realty Income buys real estate at 6.7% against 6.13% (−57bp); NHI guides 7.8% against 6.10% (−170bp). CareTrust buys at 8.9% and is priced at 4.60% — a 430bp gap, two-and-a-half to seven times the peer spread. That gap — not an operating moat — is the engine, and it can only close from the public side. Worth noting for calibration: the CBRE survey shows the SNF Class A core cap rate has gone 11.49% (mid-2014) → 11.16% (April 2025) → 10.9% (April 2026) — roughly 60bp of compression in twelve years, and still 40bp wider than April 2023. Private-pay seniors housing compressed 63–69bp in the last eighteen months alone. The asset class CareTrust owns has never had a cap-rate compression cycle; its stock has.

10.3 Embedded expectations — what must be true at $43.25

(a) The dividend-discount view is, on its face, undemanding. At a 3.61% yield with a ~78% FAD payout, the perpetual per-share growth required is simply the cost of equity less the yield:

The middle row is the whole argument. At an 8.5% cost of equity the price requires 4.89% perpetual per-share growth. CareTrust’s realised six-year Normalized FAD-per-share CAGR is 3.75% — and it was 1.2% across the four years when the stock traded at a normal multiple. The price does not require heroics; it requires more than the company has ever delivered outside a re-rating.

(b) The cross-check on cap rate gives the same answer. Capitalising ~$443M of FY2026E cash NOI, adding the credit book at par (~$1.71bn, including financing receivables and the heavy second-quarter originations) and deducting ~$602M of net debt (total debt of $1,250M including the $350M revolver draw, less ~$70M of cash and ~$578M of forward-sale proceeds receivable) across ~250.6M shares:

Today’s price corresponds to ~4.5%. A 5.3–5.9% cap rate — still a 70–130bp premium to Omega, defensible on CareTrust’s better coverage, cleaner balance sheet and superior revenue quality — maps to roughly $32–37.

© The reflexivity, quantified — and this is the finding that closes the argument. External growth funded with equity is accretive only while the FAD yield sits below the acquisition yield. Solving for the annual deployment required to add 2.5% to FAD/share (which, on top of 2.5% escalators, produces the ~5% the DDM demands) at different multiples:

Two conclusions follow. First, today’s price does not embed heroic deal volume — ~$290M a year clears the bar, against $1,764M actually deployed in FY2025 and ~$1.1bn in the first four months of 2026 alone (a ~$3.2bn annualised pace). On volume, the market is asking for very little. Second, the required volume more than doubles as the multiple compresses, and at roughly 11.2x forward FAD (about $21) equity-funded external growth becomes arithmetically impossible because the cost of equity equals the acquisition yield. That is not a theoretical construct: Strawberry Fields REIT trades at 10.3x, funds itself at ~6.85%, and closed zero acquisitions in Q1 2026 — its CEO saying “We are not changing our model to pay more” after CareTrust outbid it by $25M on a deal it had already won. The model is observable in the wild.

One caveat that cuts against the bull case in every model above, including ours. The 8.9% figure is a stabilized yield, not a year-one cash yield. When CareTrust raised guidance in May for $864.1M of newly closed investment, the increase to revenue was only ~$20M — against the ~$48M that 7.5 months at a stabilized 8.9% would imply. Rent ramps, abatements and stabilization periods therefore sit between the advertised yield and the cash that arrives, and every reverse-DCF in this section that applies 8.9% to new deployment flatters the accretion. Treat the required-deployment figures as a floor.

So what is actually embedded at $43.25 is not deal volume. It is (i) the absence of credit loss and (ii) the persistence of a 99th-percentile multiple. Internal growth is 2.5% escalators minus tenant failure. CareTrust’s own FY2022–FY2023 experience — collections of 95.5% and 97.7%, $78.5M of impairments across FY2023–FY2024, per-share FAD falling — demonstrates that this term goes negative. Omega’s history is the fuller base rate: ~$1.35bn of gross credit cost between 2017 and 2025, ~15.5% of cumulative revenue, with 20 operators at 36.5% of revenue on cash-basis recognition at the trough and the dividend frozen for 27 consecutive quarters. Sabra’s is starker still: rental income 30% below its 2018 peak in nominal dollars, AFFO per share ~23% below 2019 on ~37% more shares, and a 33% dividend cut in 2020 never reversed.

10.4 Scenarios

Assumptions stated; no price target is implied by any row.

The bull case has a specific, underappreciated card that deserves proper weight. CareTrust has roughly $1.0–1.9bn of unused debt capacity to reach even the low end of its own 4.0–5.0x target (the range depends on whether one uses management’s 0.6x basis or the honest 2.36x post-quarter figure). Deployed at 8.9% against ~5.75% marginal investment-grade debt, that is worth roughly +7% to +13% to FAD per share with zero equity issuance — genuine, contractually available accretion that requires no multiple support at all. If management ever chose to use it, the reflexivity critique would weaken materially. The reason to doubt they will is in Section 7.6: the incentive plan pays maximum for leverage below 3.0x and only threshold at 4.0x.

The bear case is not a stretch. It requires only that CareTrust’s own 2022–2023 experience repeats once, at a moment when the multiple is at its 99th percentile rather than its historical mean.

10.5 Sum of the parts

The point of the exercise is the credit book. ~15% of enterprise value and ~26% of AFFO is a portfolio of 8.4%–12.1% subordinated loans to skilled-nursing operators, carried at management’s internal model. A specialty lender would be valued near 1.0–1.2x book on that paper. At 21.6x FAD the market is paying roughly 2.5x book, an excess of ~$1.4–1.6bn or ~$6–7 per share (14–16% of the price). Adjusting only for this — valuing the loans as loans — and leaving the real estate untouched would take the stock to roughly $36–37 on its own.

10.6 Verdict

What the market is underwriting correctly: that supply is structurally constrained (first SNF inventory addition since 2017, development frozen, plant averaging 40–50 years old, transaction prices well below replacement cost); that demand is arithmetically certain (80+ population +55% by 2035); that CareTrust’s coverage is genuinely superior (2.25x EBITDAR against Omega’s 1.58x best-in-a-decade and Welltower’s 1.32x on post-acute); that the balance sheet is exceptionally strong and now investment grade; that revenue quality and the AFFO definition are unusually clean; and that management sources deals better than peers.

What it is underwriting incorrectly, in my judgement: first, it is capitalising a Medicaid-reimbursed operating asset at a private-pay duration multiple — 21.6x, above every net-lease REIT and in line with 96%-private-pay SHOP operators. Second, it is capitalising ~26% of AFFO that is subordinated loan interest, and ~4% that is interest on idle cash, at a real-estate multiple. Third, it is extrapolating a 10.6% per-share growth rate that was produced by multiple expansion, when the same machine at a normal multiple produced 1.2%. Fourth, it is pricing the absence of credit loss in an asset class whose two largest public landlords have between them destroyed roughly $2bn of value through tenant failure since 2016, in a portfolio where ~75% of rent comes from operators whose financials the company states it has not verified. No price target is offered; the embedded expectation is simply higher than the demonstrated delivery.

11. Variant Perception

Consensus. The sell side and the income-investor community treat CareTrust as a best-in-class compounder that has earned its premium: fastest per-share growth in the SNF cohort, cleanest balance sheet, newly investment grade, a proven acquisition machine with three growth engines, and a dividend raised every year. The bear argument is generally reduced to “it looks expensive,” and the counter is “quality deserves a premium.” Sell-side sentiment has drifted from Buy to Hold on valuation alone — “the bargain is gone,” “not ready to pull the trigger” — with no one disputing the business.

The strongest bull case, stated at full strength. Supply is capped by economics and by law; demand is demographically certain; and CareTrust owns the asset class with the widest cap rate in healthcare real estate while carrying the sector’s most conservative balance sheet. Asset-level cash returns have held at ~9% for seven years — this is not a business reaching for yield. Coverage at 2.25x is 42% above Omega’s best coverage in a decade, which is exactly the margin of safety you want against a Medicaid step-down that does not begin until FY2028 and is repeatedly deferred in practice. The staffing mandate is dead. Medicare rates are rising 2.4%. Every equity raise has cleared its cost of capital by 270–420bp and been priced above book, lifting book value per share 111% in three years. Care REIT was bought at a discount to NAV. And there is ~$1.0–1.9bn of untapped investment-grade debt capacity worth +7–13% to FAD per share that requires no equity and no multiple support. On that reading, 21.6x is what you pay for a genuinely better underwriter in a genuinely better-positioned asset class, and the stock compounds mid-to-high single digits per share from here with optionality on the balance sheet.

The strongest bear case, stated at full strength. The premium is not earned by per-share results; it creates them. Normalized FAD per share compounded at 3.75% over six years and fell from 2021 to 2024 while $2.28bn of equity was raised — and in the four years the stock traded at a normal 14.3x, this identical platform delivered 1.2% a year. The 10.6% since is arithmetically inseparable from a 43% re-rating. Sixty percent of the annual bonus is independent of per-share results, 40% of it is raw deployment volume with no return condition, 20% pays maximum for not using the debt capacity management advertises, and the per-share hurdle was cut three years running so that four flat years still paid out at maximum. Pay is benchmarked to market capitalisation, which is grown by issuing shares. Insiders own 0.665% and have not bought a share in the open market in five years while the stock tripled. There is no same-store disclosure and no realised-yield reconciliation, so the model’s central claim cannot be verified. ~26% of AFFO is subordinated operator credit carried at an internal model with one 100% loss already taken and a 23.7% reserve on one bucket — and Sabra just settled a par-carried, zero-allowance $300M mortgage for $200M ninety days after reporting no impairment. ~75% of rent comes from operators the company says it has not independently verified, and the largest, at 23% of rent, is 29% off its high on an unadjudicated allegation of systematic understaffing.

The three assumptions that matter most.

1. That the multiple holds. Everything else is downstream. At 21.6x the acquisition spread is 415bp; at Omega’s multiple it is ~204bp; below ~11.5x equity-funded growth is impossible. Nobody controls their own multiple.
2. That internal growth stays positive. 2.5% escalators minus credit loss. Omega ran 20 operators at 36.5% of revenue on cash basis; Sabra’s rental income is 30% below its 2018 peak. CareTrust’s own 2022–2023 shows the term can invert.
3. That the Medicaid step-down is deferred or absorbed. The FY2028–FY2032 provider-fee taper and the ~CY2028 state-directed-payment cap are dated and real, but out-year healthcare cuts have a long history of being postponed, and a peer’s disclosed net supplemental benefit actually rose in the year after enactment.

What the tape adds, and it cuts against the consensus framing. CareTrust is not a momentum trade — its Momentum factor loading is effectively zero and its Quality loading is negative in every nested model, with ~58% of return variance idiosyncratic. What it is, statistically, is a rates-and-real-estate duration instrument riding the single most in-favour industry factor in a 121-factor universe (REITs, 252-day z-score +3.84; Healthcare Providers second at +3.01) while the interest-rate factor it is short has already turned (+5.12% over 21 days, z +1.91) without the price noticing. Its factor twins are NNN, W. P. Carey, Healthcare Realty and Realty Income — every one of which trades at 11–13x. And low beta is not safety: this stock fell 67% in 2020, its ten-year Sharpe ratio is 0.43, and its entire +20% run to the current all-time high carries no company-specific catalyst at all, with Q2 results not due until 7 August 2026.

Where consensus is most likely offside. Not on business quality — the bulls are right that this is the best-run landlord in its cohort. They are offside on what the per-share record actually is, because the headline growth rates (Normalized FFO +38% in Q1 2026) are entity-level and the per-share figures (+14%) are two-thirds smaller, and because the four-year flat stretch from 2021 to 2024 has been forgotten. And they are offside on what asset class they own, having accepted a private-pay duration multiple for a portfolio whose tenants derive roughly 58% of revenue from government payors and whose largest is under a fraud-adjacent short attack.

12. Fact vs. Interpretation

13. Open Questions

1. What is the straight-line rent receivable balance, and what have cumulative write-offs been? Not separately disclosed since 2018 ($2.8M). Write-offs are charged directly against rental income rather than shown as a provision, so gross write-offs are unobservable from outside.
2. How much contractual rent is currently recognised on a cash basis, and from how many tenants? FY2025 discloses only a $3.9M rental-income reduction “related to certain tenants on a cash basis” — tenants unnamed, count undisclosed, affected rent unquantified. This is the largest single disclosure gap in the filings, and it is precisely the metric on which Omega’s distress became visible (20 operators, 36.5% of revenue at the trough).
3. What security deposits and tenant letters of credit does CareTrust actually hold? Neither is quantified anywhere in the FY2025 10-K, despite explicit reference to holding letters of credit.
4. Why has management never used the balance sheet? Running 0.4–0.9x against a stated 4.0–5.0x target for three years is either rational (equity has been cheaper) or an unstated view that leverage against SNF tenant credit is unwise through a reimbursement cycle. Section 7.6 supplies a third explanation — the bonus pays maximum below 3.0x — but management has never addressed the question directly.
5. Will there be an inaugural investment-grade bond, and will it fund acquisitions rather than refinance? The CFO indicated ~+130–140bp for ten-year paper and that it is “on our radar.” This is the single clearest test of whether growth can be funded without equity.
6. What were the realised yields on the FY2023 and FY2024 vintages? No same-store disclosure exists and no asserted “stabilized yield” is ever reconciled to a realised one. Without this, the model’s central claim is unauditable.
7. RESOLVED on further review — partially. The maturity profile is obtainable: no rent expires before 2031, with a weighted-average remaining term of ~11 years (SNF ~10, seniors housing ~17). What remains absent is a year-by-year lessor future-minimum-rent table. The more useful open question is the renewal mechanics: options sit with the tenant and can reset rent downward — Ensign’s 1 December 2025 five-year extension "triggers a base rent adjustment … reducing the rent by approximately $0.6 million." There is also a landlord capex put (Ensign and Pennant can require CareTrust to fund capex up to 20% of initial investment) and tenant purchase options on 12 properties representing 4.6% of rent ($225.7M).
8. How much of the reported EBITDAR coverage lag matters? Coverage appears only in furnished supplements, never in a filed document, so the reporting lag cannot be established from EDGAR. Sabra’s example — a par-carried, zero-allowance $300M mortgage settled for $200M ninety days later — suggests peer coverage and carrying-value disclosures can lag credit reality by roughly a year.
9. What is the magnitude, for skilled nursing specifically, of the OBBBA provider-fee taper and the CMS state-directed-payment cap? The calendar is known; the dollars are not. Hospital peers quantify their own exposure at 32–35% of the supplemental stream by 2032 but say they cannot estimate the managed-care rule.
10. Do the June 2026 understaffing allegations against Ensign touch any CareTrust-owned facility? Unresolved, and material given 23% rent concentration.
11. What is the true fully diluted share count? Management guides 234M weighted-average for FY2026; 236.2M were outstanding on the 6 May 2026 cover; unsettled forwards (~9.5M at 31 March plus 12.5M–14.375M from the May offering) imply ~250–260M fully settled. Every multiple in Section 10 moves with this.
12. What are the components of the $120.4M “accounts payable, accrued liabilities and deferred rent liabilities” balance? Its increase contributed ~$52M of operating cash flow over two years; the split between tenant prepaid rent and accrued incentive compensation is undisclosed.
13. Will the SHOP platform scale, and at what cost? Four communities, 7%+ going-in yields, compressing cap rates, and management’s own admission of being outbid by higher-cost-of-capital rivals.

14. What Must Be True

Bull case

Bear case

One dated observation belongs in both columns: FY2028 is a convergence point. Six separate items land in a single window, all of them beyond FY2026 guidance and beyond today’s 2.25x coverage print: the US state-directed-payment phase-down (January 2028), the Section 71117 uniformity-waiver compliance deadline for nursing homes (July 2028), a probable PDPM recalibration/clawback (FY2028–29), the UK Fair Pay Agreement’s first settlement (April 2028, with only £500M allocated against 1.5M workers), the Casey Commission’s Phase 2 report on UK social-care funding (2028), and the cumulative effect of US and UK immigration restrictions on direct-care labour supply (Penn estimates ~395,000 US direct-care jobs lost by 2028; UK international care-worker recruitment has already fallen from ~105,000 to ~50,000 after care workers were removed from the visa route in July 2025). Neither the bull nor the bear case is testable on 2026 data. Both resolve in 2028.

The cleanest single discriminator is S1/B1 restated as one test: can CareTrust compound Normalized FAD per share at high single digits while its own multiple is compressing? It has never done so. Four years of evidence (FY2019–FY2023, 1.2% a year at 14.3x) say it cannot. Two years of evidence (FY2024–FY2026E, ~13% a year at a re-rating multiple) say the market believes it can. That question, and not the quality of the portfolio, decides the outcome.

15. Source Appendix

See Appendix B below for the full source list with URLs and access dates. Primary sources relied on include: CareTrust REIT FY2021–FY2025 Forms 10-K and the Q1 2026 Form 10-Q (CIK 0001590717); the FY2019–FY2025 and Q1 2026 earnings releases and financial supplements (8-K Exhibits 99.1 and 99.2); DEF 14A proxy statements 2022–2026; the complete Form 3/4/5 corpus (87 filings, 2021–2026); the 424B5 prospectus supplements of 18 February and 18/20 May 2026; the Care REIT plc Rule 2.7 announcement and scheme documents; Q1 2026 and Q3 2025 earnings-call transcripts; SEC EDGAR XBRL company facts; the CBRE US Senior Housing & Care Investor Survey (1H2014 and 11th–18th editions); Irving Levin/LevinPro LTC transaction data; NIC MAP inventory and occupancy data; Omega Healthcare, Sabra, NHI, LTC, Strawberry Fields, NNN, W. P. Carey, Welltower, Ventas and American Healthcare REIT filings and calls for comparables; AZI price history and valuation-index percentiles; FactorsToday factor loadings and risk-adjusted return series; and the ROIC.ai data and transcript service.

Note on one limitation: two items — the PACS Group recovery and elements of the skilled-nursing transaction-market read — rest on company press releases and filings rather than on independent trade-press corroboration. No conclusion here depends on a secondary source alone, and every material figure has been traced to a filing, a company release, or a named third-party survey.

Sections 1–15 above contain no recommendation and no price target; the sole exception is the clearly-labeled opinion block at the front, which is the author’s own subjective view. Nothing here is investment advice.

APPENDIX A — Standard Diligence Questionnaire

CareTrust REIT, Inc. (NYSE: CTRE) · Report date 25 July 2026 · Reference price $43.25

A standard diligence checklist applied to the company, supplemental to the analysis above. Labels: FACT / INTERPRETATION / ASSUMPTION.

General

What thoughtful questions have other investors asked about this company?

The sell-side Q&A is notably unsceptical, which is itself a finding. Across the Q3 2025 and Q1 2026 calls the genuinely probing questions were:

• Richard Anderson (Cantor Fitzgerald) asked the best question in the file: given that the triple-net book delivers only “low single-digit” organic growth, is SHOP about expanding external growth or about manufacturing a better organic-growth story? The CEO conceded “it really is 1A, 1B there.” This is management admitting the structural limitation of the model.
• John Pawlowski (Green Street) pressed on UK coverage drifting down two quarters after the Care REIT close; management called it “idiosyncratic… not a cause for any concern” without quantifying it.
• Juan Sanabria (BMO) asked how large the loan book is allowed to get and whether operators hold repurchase options — eliciting the disclosure that some “sale-leasebacks” are accounted for as financing receivables because of purchase options 9–10 years out.
• Farrell Granath (BofA) asked why peers describe rising SNF competition while CareTrust keeps sourcing volume.
• Michael Carroll (RBC) asked directly what rate CareTrust could issue at post-upgrade (~+130–140bp for ten-year paper).

Questions the sell side has not asked, and should: why there is no same-store disclosure; why no asserted “stabilized yield” is ever reconciled to a realised one; why leverage runs at 0.4–0.9x against a stated 4.0–5.0x target when the bonus pays maximum below 3.0x; why no buyback has ever been authorised; and how much rent is on cash-basis recognition.

Cyclicality and the Nature of Earnings

Are earnings at a cyclical high or low? INTERPRETATION: at a cyclical high on the operator side, and at a structural high on the landlord side. SNF occupancy passed 87% in Q1 2026 — the highest since 2016 — and SNF rent growth exceeded 5%, the fastest since 2008. Tenant EBITDAR coverage of 2.25x is well above Omega’s 1.58x (its best in a decade). The CMS staffing mandate is dead and Medicare rates are rising 2.4%. That combination is about as good as this asset class gets. The offsetting point is that the reimbursement cycle has a dated downturn scheduled (OBBBA provider-fee taper FY2028–FY2032; CMS state-directed-payment cap ~CY2028).

Driven by the external environment or internal actions? Both, roughly equally. Externally: occupancy recovery from the 2021 trough, Medicaid rate normalisation and a benign rate path. Internally: ~$4.69bn of deployment since FY2023 at 8.6–9.9% yields, funded by equity priced at a 4.6–5.7% FAD yield. Strip the external tailwind and the internal action still produced only 3.75% annual per-share FAD growth over six years.

How stable are revenues? FACT: unusually stable in form, less so in substance. Contractual triple-net rent under long master leases with cross-default, 100% collection in 2020, 2021, 2025 and Q1 2026, and essentially no straight-line rent. But collections were 95.5% in Q4 2022 and 97.7% in FY2023; ~22.5% of revenue is loan interest that reprices and repays (guided down 7–9% in FY2026 on $145M of assumed repayments); and ~75% of contractual rent comes from operators with no public financials.

Outlook for products/services? Demand is arithmetically certain: the US 80+ population goes from ~14.7M (2025) to ~23M (2035), +55%, and the oldest boomers turn 80 in 2026. Penetration of eligible seniors is only ~7–10%.

How big will this market be — growing, shrinking, domestic or international? ~15,000 US skilled-nursing facilities and ~1.37M nursing-care beds, with supply flat to shrinking — Q1 2026 was the first inventory addition since 2017 and development remains “frozen.” NIC estimates the US needs ~549,000 additional seniors-housing units by 2028 against deliveries at roughly one-third of requirement. CareTrust is now ~83% domestic and ~17% UK by revenue.

Business Quality and Competitive Moat

Is the industry getting more or less competitive? More, and specifically for landlords. Owner-operators were 75% of H2 2024 SNF buyers; REITs and real-estate funds ~21%. Sabra’s CEO: private buyers “are buying OpCo and PropCo, and they also are feeding ancillary businesses. So as a buyer of real estate, we just cannot compete with that.” CareTrust’s own stated stabilized yields fell from 9.8% (FY2023) to 8.6% (FY2025), and going-in yields from 9.14% to 8.10%.

How profitable is the business (ROIC, ROE)? GAAP ROE was 9.23% in FY2025 (and negative in FY2022) — largely meaningless for a REIT. The economically meaningful measures: cash return on average gross invested capital of 8.65%–9.33% across seven years, a seven-year high in FY2025; Normalized FFO over average book equity of 10.4% (down from ~16% only because book was marked up by equity issued at 1.9–2.6x book). The correct sector analog for “ROIC” is the investment spread: ~8.9% acquisition yields against a 4.62% forward FAD cost of equity — ~415bp today, but only ~204bp at the multiple CareTrust averaged from 2019 to 2023.

How profitable is the industry — how many competitors, what barriers to entry? For operators, barriers are real: CON bed licences, licensure, and construction economics that do not pencil (build cost ~$140k–300k/bed versus a $105,600/bed transaction average). Ensign earns ~22% ROE. For landlords, barriers are close to nil — anyone with capital can buy a building and sign a lease. The competitive set is Omega, Sabra, NHI, LTC, Strawberry Fields, Welltower at the margin, family offices, private OpCo/PropCo buyers, and now Ensign’s own captive REIT.

Can the business be easily understood? Mostly yes — collect rent on long net leases. Two things make it harder than it looks: ~26% of AFFO is subordinated loan interest carried at an internal fair-value model, and roughly 167 of the headline property count are lending exposures rather than owned buildings.

Can it be undermined by foreign low-cost labour? No. Care is delivered locally and cannot be offshored. The relevant labour risk is domestic wage inflation in the tenant’s cost stack (labour is ~59% of a facility’s costs), which compresses coverage — and in the UK, the April 2025 National Living Wage (+6.7%) and employer National Insurance increases raised provider costs ~10%, a fact absent from the 10-K.

Do brands matter? No, at the landlord level. A tenant signs because the location and licence are mission-critical, not because CareTrust owns the building. CMS star ratings matter to the operator’s referral flow; management’s claim that its tenants beat sector averages on star ratings is directionally supportive but self-selected and unverified.

What is the nature of competition? Price competition for assets, mediated entirely by cost of capital. CareTrust’s edge is cheap equity plus off-market relationship sourcing. The clearest illustration: Strawberry Fields’ CEO stating that “CareTrust came and stole it from us … they offered like $25 million more than us.”

Customers’ switching costs? Real but two-sided. Licensure transfer takes months and CON restricts changes of ownership; master leases are cross-defaulted with all-or-none renewal. But a vacant SNF cannot be re-let or repurposed quickly, so the landlord is trapped too — evidenced by CareTrust paying $12.3M to terminate and assign the Covenant Care leases.

Financial Condition and Balance Sheet

Assets not fully recognised on the balance sheet? The portfolio is carried at depreciated cost, so appreciation is unrecognised — gross real estate of ~$4.46bn versus a market-implied real-estate value of ~$9.8–10.3bn. Also unrecognised: the option value of ~$1.0–1.9bn of unused investment-grade debt capacity.

Off-balance-sheet liabilities? FACT: earn-out obligations of up to $42.5M (a $10.0M SNF earn-out to October 2026 and a $32.5M five-SNF earn-out running December 2026–2028); $6.2M of committed capex; and an Ensign/Pennant option requiring CareTrust to fund capex up to 20% of initial investment at the tenant’s election. Operating lease ROU assets of $30.0M in the UK. Unfunded loan commitments are not disclosed in aggregate. No pension, no material litigation reserve.

How conservative is the accounting? Mixed, tilting conservative. Conservative: straight-line rent effectively zero for five years and deducted from FAD; fair-value loan marks excluded from Normalized FFO/FAD; no normalizing items at all in FY2026 guidance; operating cash flow has exceeded AFFO cumulatively; ICFR effective every year with no restatement and no auditor change (Deloitte since 2019). Aggressive or opaque: 100% of stock compensation added back to FAD ($0.05/share); the ~$1.0bn credit book at fair value under an internal model rather than amortised cost with a CECL reserve; $20.7M of Care REIT transaction costs capitalised via asset-acquisition treatment, leaving zero goodwill; rent write-offs charged directly against revenue rather than shown as a provision; no same-store metric; no lease-expiration schedule; no security-deposit or letter-of-credit quantification; and Deloitte’s FY2025 ICFR opinion excluded Care REIT (18.5% of assets).

How CapEx-hungry is the business? Genuinely light, and this was tested. Cumulative capex FY2019–FY2025 was $61.9M = 4.7% of cumulative Normalized FAD, with committed capex of only $6.2M at year-end 2025 ($5.1M of it rent-generating). The triple-net claim holds. Caveat: FY2025 capex jumped 86% to $15.0M and the new SHOP platform puts capex on the landlord — expect this to widen.

Capital Allocation and Management

How much FCF does the business generate, how does management use it, what is the philosophy? FY2025 operating cash flow was $394.0M against $259.3M of dividends — retaining $134.7M. Across seven years: CFO $1,366M, dividends $927.7M, retained cash $438.7M covering just 10.2% of the $4.30bn of new capital deployed. The philosophy is explicit and unusual: fund essentially everything with equity (81.9%), keep leverage far below the stated target (0.4–0.9x versus 4.0–5.0x), and recycle nothing into buybacks.

Significant acquisitions recently? Yes — ~$4.69bn since FY2023, including Care REIT plc ($840.5M all-in, closed 8 May 2025), a $437M twelve-SNF portfolio (October 2025), $628M in April 2026 including a $380.3M fifteen-SNF California sale-leaseback, and $119M in April 2026. Care REIT was bought at a 9.4% discount to EPRA NTA — the best decision in the record.

Buying back shares? Never. Not once, and no authorisation has ever existed. Verified across every issuer-purchase table in the five-year corpus. The stock traded at $16.93 in May 2022 — a 9.3% FAD yield — and management issued $48.1M of equity at $20.00 instead.

Issuing large amounts of new shares to insiders? Grants are meaningful but not egregious in share terms: 1.03M shares granted across five years against ~223M outstanding, with $16.7M withheld for taxes. Stock compensation rose $5.2M → $6.1M → $11.9M (FY2023–FY2025). A new LTIP Unit class was created in December 2025, so CareTrust no longer owns 100% of its operating partnership.

Compensation policy of directors and management? This is the central governance finding. The 2025 annual bonus: 40% Normalized FFO/share, 40% “total value of new investments closed during the year” with no per-share, ROIC, spread or yield condition, and 20% for low leverage — maximum at ≤3.0x, only threshold at 4.0x, against a publicly stated 4.0–5.0x target. FY2025 paid 300% of target (the per-share hurdle cleared by 0.06%); the CEO’s $2.5M target bonus paid $7,750,000 on total reported compensation of $10,002,522. The per-share hurdle was set below the prior year’s actual in 2022, 2023 and 2024, so four flat years of Normalized FFO/share still paid maximum. Long-term incentives hard-wire volume too: the 2025 Outperformance Grant triggers on “>$750M in capital deployment inclusive of a strategic M&A transaction,” earning the CEO $3,396,043. Pay is benchmarked explicitly to market capitalisation. Say-on-pay drew only ~79% support in 2025, and the committee’s response to the objection was to make the volume award permanent and formulaic.

Motivations of management? INTERPRETATION: genuine operating conviction combined with incentives that reward size. The team’s healthcare pedigree is real — the CEO is a former licensed nursing-home administrator, several executives came out of Ensign, and the “by operators, for operators” framing shows up in tenant selection and coverage ratios. But insiders own 0.665% collectively, the new CFO owns zero, and there have been no code-P open-market purchases in five years while the stock tripled — against a coordinated ~$1.09M insider buying cluster at $10.50 in August 2015, which demonstrates they will buy when they think it cheap. Governance in form is sound (six directors, annually elected, no classified board, independent chair, no disclosed Item 404 transactions), though the CEO is the founder’s brother-in-law and the founder rejoined an expanded board effective January 2026.

Valuation and Market Data

Is the stock an ADR, MLP, or K-1 issuer? No. CareTrust is a Maryland-incorporated domestic REIT listed on the NYSE, issuing a Form 1099-DIV — not a K-1. It moved from Nasdaq to the NYSE in May 2022. No preferred stock is outstanding (zero of 100M authorised).

Dividend policy? Quarterly, raised every year since 2019 and never cut: $0.90 (2019) → $1.34 (2025) → $1.56 annualised (2026, +16.4%), a 3.61% yield. FAD payout has risen from 63.8% to ~78–81% — roughly half the dividend growth came from expanding the payout, not from cash-flow growth (dividend CAGR 6.85% versus FAD/share 3.75%). REIT rules require distributing ≥90% of taxable income. FY2024 tax character: 25.8% of the distribution was a return of capital because “aggregate cash distributions exceeded our annual earnings and profits”; FY2025 was 0% ROC. No special dividends.

How profitable is the business? See above — the meaningful figure is a stable ~9% asset-level cash return and a ~415bp investment spread that is ~204bp at a normalised multiple.

Is net income diverging from cash from operations? Yes, structurally and legitimately. CFO/net income ran 1.8x–2.9x from FY2019 to FY2024, compressing to 1.23x in FY2025 as $31.5M of disposition gains and $15.8M of unrealized loan marks inflated GAAP earnings. FY2022 produced a GAAP loss of $7.5M on $79.1M of impairments while Normalized FAD was $152.4M. The more useful comparison — CFO versus AFFO — shows no divergence: cumulative CFO of $1,366M exceeded cumulative Normalized FAD of $1,330M. One caveat: FY2025 CFO exceeded Normalized FAD by $34.0M, and that excess is a working-capital swing (a $28.0M increase in payables/accrued/deferred rent), not earnings quality.

Risks and Downside

What factors would cause the stock to decline? In order of importance: (1) multiple compression — at 21.6x forward FAD and the 99.3rd percentile of its own price-to-book history, a re-rate toward the SNF cohort (Omega 16.0x, Sabra 14.0x) is the largest single risk and simultaneously collapses the growth engine; (2) a tenant credit event, especially at Ensign (23% of rent, currently 29% off its high on unadjudicated understaffing allegations); (3) a Medicaid supplemental-payment reduction as the OBBBA taper and CMS state-directed-payment cap bite from ~FY2028; (4) a loan-book loss the internal fair-value model has not yet recognised; (5) rising long rates — the stock carries a −0.35 interest-rate factor loading and fell 23% on the post-election rate back-up in late 2024; (6) acquisition-yield compression reducing the spread; (7) a UK or SHOP execution stumble, with 18.5% of assets outside the FY2025 control audit and currency unhedged.

Risk of a catastrophic loss? Low. 100% unsecured debt at a 4.294% weighted average, fully fixed or hedged, nothing due before 2028, honest leverage of 1.3–2.4x against a 4.0–5.0x target, ~100% unencumbered assets, dual investment grade, $850M of undrawn revolver plus ~$879M of ATM capacity, and no going-concern language anywhere in five years of filings. The plausible bad outcome is a de-rating plus flat-to-down per-share cash flow — a ~35–40% drawdown of the kind seen in 2021–22 (−31%) — not insolvency.

Chance of a total loss? Negligible. Real assets, low leverage, investment grade, positive cash flow through COVID. The instructive precedent is that the 2020 drawdown reached −67.4% on occupancy collapse and liquidity fear without the company ever being at risk of failure — so the tail is severe mark-to-market pain, not permanent capital loss.

Recent News and Events

Has the business environment changed recently? Yes, favourably on cost and unfavourably on competition. Favourable: the CMS minimum-staffing mandate was vacated in April 2025 and legislatively blocked into the early 2030s, removing the sector’s largest cost threat; the proposed FY2027 SNF Medicare rule carries +2.4%; SNF occupancy hit a decade high above 87% and rent growth its fastest since 2008. Unfavourable: OBBBA (enacted 4 July 2025) freezes provider-fee safe harbours and steps expansion-state rates down 0.5%/yr from FY2028 to FY2032, with the CMS state-directed-payment cap biting ~CY2028; and private OpCo/PropCo buyers are compressing acquisition yields. The single most consequential recent event is not CareTrust’s own: Hunterbrook (8 June 2026) and Muddy Waters (11 June 2026) alleged a “deliberate understaffing scheme” at Ensign, CareTrust’s 23%-of-rent largest tenant, which fell ~29% from its March 2026 high despite beating and raising. Unadjudicated.

Significant acquisitions? Covered above — ~$1.1bn closed in the first four months of 2026 alone at ~8.9%, plus a $360M pipeline over half of which is UK.

Change in accounting policies? No change in policy, but three presentational items matter: Care REIT was accounted for as an asset acquisition rather than a business combination, capitalising $20.7M of transaction costs and leaving zero goodwill; ALF/ILF properties were reclassified into “senior housing triple-net” in FY2025, breaking comparability; and the critical audit matter shifted in FY2025 from the fair value of held-for-sale real estate to impairment of held-for-investment real estate, centring on management’s estimated hold period and lease coverage ratios — a subtle escalation in audit focus.

Recent changes — new markets, facilities, management? New markets: the United Kingdom (zero to 17% of revenue in four quarters) and a SHOP/RIDEA operating platform (four communities). Management: CFO Bill Wagner retired 31 December 2025, succeeded by Derek Bunker — who had been a paid consultant on the Care REIT transaction from January to June 2025 and came from Ensign and Pennant; founder Greg Stapley rejoined the board effective 1 January 2026 on a board expanded from five to six seats; CIO Mark Lamb resigned in November 2022, succeeded by James Callister. Ratings: Fitch BBB− (May 2025) and Moody’s Baa3 (27 April 2026). Capital: a new $1.0bn ATM (17 February 2026) and a 12.5M-share (14.375M with the option) forward-sale offering priced 18 May 2026 at a $40.00 initial forward price.

APPENDIX B — Source Appendix

CareTrust REIT, Inc. (NYSE: CTRE) · Report date 25 July 2026

Primary sources first. Every material figure above traces to an entry below. Third-party sources are labeled as such.

1. CareTrust REIT SEC filings (CIK 0001590717)

The trailing 60-month corpus was enumerated and mirrored locally (183 documents plus 87 raw Form 3/4/5 XML filings). Form-type census, July 2021 – May 2026, excluding 424B/FWP/144 noise: 81 Form 4, 56 Form 8-K, 15 Form 10-Q, 7 DEFA14A, 6 Form 3, 5 DEF 14A, 5 Form 10-K, 4 ARS, 2 S-3ASR, 1 Form 25, 1 Form 8-A12B. Zero NT 10-K/NT 10-Q, zero Item 4.01 (auditor change), zero Item 4.02 (non-reliance).

Annual reports (Form 10-K) — filed 12 Feb 2026 (FY2025, ctre-20251231.htm), 12 Feb 2025 (FY2024), 8 Feb 2024 (FY2023), 9 Feb 2023 (FY2022), 16 Feb 2022 (FY2021). FY2025 sections relied on: Consolidated Balance Sheets, Income Statements, Statements of Equity and Cash Flows; Note 3 (Care REIT acquisition, asset-acquisition treatment, capitalised transaction costs); Note 4 (Real Estate Investments; Lease Amendments and Terminations); Note 6 (Other Real Estate Related and Other Investments — loan schedule, rates, maturities, interest income); Note 7 (Derivatives and Hedging); Note 9 (Debt); Note 10 (Equity/ATM); Note 16 (Commitments and Contingencies — earn-outs, committed capex); Item 2 (portfolio and geographic concentration); Item 5 (dividends, tax character, issuer purchases); Item 7 MD&A pp. 55–65; Item 7A (swaps, FX, GBP462.4M intercompany debt); Item 9A and the Deloitte & Touche LLP internal-control opinion (unqualified; Care REIT plc excluded from scope — 18.5% of total assets, 11.5% of revenues); Critical Audit Matter (shifted in FY2025 to impairment of held-for-investment real estate, centring on hold period and lease coverage).

Quarterly report — Form 10-Q for Q1 2026, filed 7 May 2026 (ctre-20260331.htm): balance sheet, income statement, cash flows, fair-value and debt notes, cover-page share count (236,240,235 shares as of 6 May 2026).

Earnings releases and financial supplements (Form 8-K, Exhibits 99.1 and 99.2) — the source of record for FFO/FAD, guidance, debt schedules and Net Debt/EBITDA reconciliations:

• Q1 2026: filed 7 May 2026, accession 0001628280-26-032150 (ex991-ctreq12026er.htm) — raised guidance to $2.00–2.04 Normalized FFO/share and $1.98–2.02 Normalized FAD/share on 234M shares; interest income $97–99M; $145M of loans assumed repaid; debt schedule at a 4.294% weighted average, 100% fixed or hedged; $0.39 dividend (+16.4%); $350M revolver draw; $363.6M forward settlement.
• FY2025/Q4 2025: filed 12 Feb 2026, accession 0001628280-26-007672 (ex991-ctreq42025er.htm, exhibit992-ctreq42025fin.htm) — FY2025 net income $320.5M/$1.57; Normalized FFO $359.7M/$1.76 (+17%); Normalized FAD $360.0M/$1.76 (+14%); $1.8bn invested at 8.6%; $1.1bn of equity raised plus $242.5M of unsettled forwards; initial FY2026 guidance with the full FAD bridge (D&A $101M, deferred financing fees $5M, stock compensation $12M, straight-line rent −$14M, non-cash financing-receivable revenue −$2M) and guidance detail (cash rental revenue $430–436M, interest income $88–92M, G&A $57–59M, interest expense $45–46M).
• FY2024: filed 12 Feb 2025, accession 0001628280-25-005119 — Q4 2024 investments $696.5M at 9.9%; 15.9M shares for $507.8M gross (~$31.94); revolver upsized to $1.2bn; 98.8% collections; net debt/EBITDA 0.5x; new $750M ATM.
• FY2023: filed 8 Feb 2024, accession 0001628280-24-003868 — FY2023 quarterly Normalized FFO/share $0.35/$0.35/$0.35/$0.36 and FAD/share $0.37/$0.36/$0.37/$0.37; impairments $1.886M/$21.392M/$8.232M/$4.791M; FY collections 97.7%; investments $288.1M at 9.8%.
• FY2022: filed 9 Feb 2023, accession 0001628280-23-002959 — “Normalized FFO per share for the quarter and the year of $0.38 and $1.49”; Q4 collections 95.5%; Q4 impairment $5.356M.
• FY2021: filed 16 Feb 2022, accession 0001628280-22-002843 — FY2021 quarterly Normalized FFO/share $0.36/$0.37/$0.38/$0.39 and FAD/share $0.38/$0.40/$0.40/$0.41; diluted weighted-average shares 95.4–96.6M.
• FY2020 (accession 0001628280-21-001800) and FY2019 (0001628280-20-001903) releases for the earlier per-share series.

Proxy statements (DEF 14A) — filed 13 Mar 2026 (ctre-20260312.htm), 7 Mar 2025, and the 2024/2023/2022 predecessors. Relied on for: the 2025 annual cash-incentive metric table (Normalized FFO/share 40%; Capital Deployment 40%, defined as “total value of new investments closed during the year, including acquisitions and strategic M&A transactions”; average quarter-end net debt/normalized run-rate EBITDA 20% with Threshold 4.0x / Target 3.5x / High 3.0x; payout 50%/100%/200%/300%); FY2025 actuals (Normalized FFO/share $1.7602 vs. “High” $1.7591; deployment $1,764M vs. “Super” $1.5bn; leverage 0.89x; final achievement 300%); Summary Compensation Table (CEO 2025 total $10,002,522, including a $7,750,000 non-equity incentive payout on a $2.5M target); the 2025 Outperformance Grant terms and the $3,396,043 earned; the January 2025 discretionary award citing “over $1.5 billion of capital deployed … while reaching a record low leverage ratio … of 0.40x”; the relative-TSR peer group (14 names, including Diversified Healthcare Trust and Medical Properties Trust); the compensation peer group and its explicit market-capitalisation selection criterion; beneficial ownership (all officers and directors 1,484,199 shares = 0.665%); the disclosure that “Mr. Stapley is Mr. Sedgwick’s brother-in-law”; and ~79% say-on-pay support in 2025. Successive proxies were compared to establish that the Normalized FFO/share hurdle was set below the prior year’s actual in 2022, 2023 and 2024, with the 2024 proxy stating the levels were lowered “to reflect expected lower revenue levels.”

Insider filings — the complete Form 3/4/5 corpus, 87 filings, parsed from raw XML. Findings: zero code-P open-market purchases in five years; one open-market sale (William Wagner, 35,000 shares at $29.80 = $1,043,000, 4 September 2024, no 10b5-1 footnote); 41 grants (code A) plus 8 Table II acquisitions; 38 tax-withholding dispositions (code F) totalling ~$16.7M; one gift. A coordinated purchase cluster on 13 August 2015 at $10.50 (Stapley ~$525k, Wagner ~$367k, Kline ~$262k, Sedgwick ~$199k) establishes that the team does buy when it believes the stock cheap.

Registration and offering documents — S-3ASR filed 18 Feb 2026; 424B5 filed 18 Feb 2026, accession 0001140361-26-005886 (new $1,000,000,000 ATM programme dated 17 Feb 2026, replacing the 21 Jan 2025 programme, with $367.0M of forward sale agreements outstanding under the prior programme at termination); 424B5 filed 18 and 20 May 2026, accessions 0001140361-26-021896 and 0001140361-26-022138 (12,500,000 shares, 14,375,000 with the underwriters’ option, on forward sale agreements with Wells Fargo Securities and J.P. Morgan Securities, initial forward sale price $40.00, physical settlement anticipated within ~one year).

Material 8-K events relied on — 10 Dec 2021 (Item 5.02, founder Greg Stapley resigns as CEO; David Sedgwick promoted, disclosed as Stapley’s brother-in-law); 1 Jul 2022 (Stapley leaves the board; Diana Laing becomes independent Chair); 28 Nov 2022 (CIO Mark Lamb resigns; James Callister promoted); 19 Dec 2022 and 19 Dec 2024 (credit facility, ultimately upsized to $1.2bn to 2029); 11 Mar 2025 (Care REIT plc Rule 2.7 offer); 14 May 2025 (Care REIT completion 8 May 2025: $595.4M equity + $245.1M net debt = $840.5M); 2 Jun 2025 ($500M term loan, explicitly to repay the revolver); 14 Aug 2025 (23.0M shares at $32.00 = $736.0M gross); 23 Sep 2025 (Item 5.02, CFO Wagner retirement; Derek Bunker appointed, having been a paid consultant on the Care REIT transaction January–June 2025; formerly of Ensign and Pennant); 27 Oct 2025 (Stapley rejoins the board effective 1 January 2026); 17 Dec 2025 (LTIP Units created; CareTrust ceases to own 100% of the operating partnership’s LP interests); 1 Nov 2024 (15.9M shares at $32.00). Note: CareTrust filed no Item 2.01 acquisition 8-K in the entire five-year window — all deal disclosure sits in 10-Q/10-K notes and furnished Item 7.01 supplementals, which is also why EBITDAR coverage ratios appear in no filed document.

SEC EDGAR XBRL company-concept API (via scripts/edgar.sh) — us-gaap:RealEstateInvestmentPropertyAtCost and …Net (gross and net real estate FY2013–FY2025), us-gaap:StraightLineRent (FY2014–Q1 2026), us-gaap:DeferredRentReceivablesNet (last tagged 31 Dec 2018 at $2.8M), us-gaap:PrepaidExpenseAndOtherAssets, us-gaap:NotesReceivableNet. Accessed 25 July 2026.

2. CareTrust management commentary

• Q1 2026 earnings call, 8 May 2026 (via ROIC.ai) — Lauren Beale (CAO), David M. Sedgwick (President/CEO), James B. Callister (CIO), Derek J. Bunker (CFO). Source for: $245M closed in Q1 at 8.8%; ~$865M across 12 transactions since April at ~8.9%; YTD ~$1.1bn at ~8.9% ($705M US triple-net, $225M US loans, $160M UK, remainder SHOP); $360M pipeline over half UK; Normalized FFO $107.4M (+38%) / $0.48 (+14%) and Normalized FAD $107.6M (+33%) / $0.48 (+12%); EBITDAR coverage 2.25x, EBITDARM 2.79x; 100% collections; UK coverage 1.75–1.8x, above 2.0x on EBITDA; net debt/EBITDA 0.6x against a 4.0–5.0x target; indicated ~+130–140bp for a ten-year IG issue and that any bond “will be denominated in USD”; SHOP cap rates “compressed 50 bps or more” with class-A primary at “a five handle”; the concession that rivals with worse cost of capital win SHOP deals; SNF pricing “below a 9% yield … to get the deal”; and the G&A explanation that the increase was “almost entirely due to hitting key KPIs for STI given our performance and guide for FFO and investment spend.”
• Q3 2025 earnings call, 6 November 2025 (via ROIC.ai) — adds William Wagner (retiring CFO). Source for: Normalized FFO +55.5% in dollars versus +18.4% per share; the CFO’s acknowledgement that “the timing gap between funding and closings … represented a short-term headwind”; the August 2025 $736M raise; net debt/EBITDA 0.43x, net debt/EV 2.4%, fixed-charge coverage 11x; asset-class yield guidance (US SNF “a 9 handle,” UK “8.5% or higher,” seniors housing “7% or higher”); the Covenant Care workout; the PACS forbearance exchange with Richard Anderson; Green Street’s question on UK coverage drift; and Richard Anderson’s exchange on SHOP versus “low single-digit” organic growth.
• ROIC.ai list_earnings_calls confirms 20 available calls, Q2 2021 through Q1 2026.

3. Peer and comparable-company filings

Read directly from EDGAR for the comparable set, all Q1 2026 (31 March 2026) balance sheets with post-quarter updates through July 2026:

• Omega Healthcare Investors (OHI, CIK 888491) — Forms 10-K FY2016–FY2025 and Q1 2026 10-Q; earnings 8-K exhibits 3Q17–1Q26; XBRL company facts. Source for the SNF-landlord credit base rate: ~$1.35bn of gross credit cost 2017–2025 (~15.5% of cumulative revenue); 20 operators at 36.5% of revenue on cash-basis recognition at YE2022; Orianna ($46M rent → $16.8M re-tenanted, $233M of direct-financing-lease impairments, a $30.75M securities-class-action settlement); Agemo/Signature ($57.6M → $22.8M); Consulate/LaVie ($99.6M → $37.2M); Gulf Coast; Guardian ($46.8M of mortgage principal forgiven); Maplewood (a $323.8M revolver on non-accrual with zero interest income in 2024–2025, and the July 2020 transaction in which Omega lent Maplewood the funds Maplewood used to pay Omega $55.4M of lease obligations, recognised as rent); Genesis Chapter 11 (July 2025, unresolved, with the creditors’ committee challenging Omega’s collateral); the dividend frozen at $0.67 for 27 consecutive quarters before a raise to $0.68 on 23 July 2026; and Q1 2026 core EBITDAR coverage of 1.58x, “the highest in over a decade.” FY2026 AFFO guidance $3.19–3.25.
• Sabra Health Care REIT (SBRA, CIK 1492298) — Forms 10-K FY2016–FY2025, 10-Qs through Q1 2026, earnings 8-K exhibits, and the 21 July 2026 business update. Source for: rental income 30% below its 2018 peak in nominal dollars; cumulative rent write-offs ~$164M, real-estate impairments ~$302M, equity-method other-than-temporary impairment $221.9M (Enlivant: $352.7M invested to zero, ~$317.6M of cash destroyed); the 33.3% dividend cut announced 25 March 2020, never reversed, with no increase since February 2018; AFFO/share ~23% below 2019 on ~37% more shares; and the Recovery Centers of America mortgage — $300M carried at par with zero allowance at 31 March 2026, settled 30 June 2026 for $200M. Q1 2026 call (30 April 2026) for the CEO’s statement on private OpCo/PropCo buyers and the CIO’s “low 7% range” on marketed SNF product.
• National Health Investors (NHI), LTC Properties (LTC), Strawberry Fields REIT (STRW) — Q1 2026 10-Qs, 8-Ks and earnings calls. STRW’s Q1 2026 call is the source for the CEO’s statement that “CareTrust came and stole it from us … they offered like $25 million more than us,” that “we lost one deal to Welltower and one deal to CareTrust,” that “we are not changing our model to pay more,” and that the lost deal “traded at an 8.5% cap” — alongside zero acquisitions closed in Q1 2026. NHI’s 21 April 2026 8-K for the $560M sale of 32 SNFs and 3 ILFs to National HealthCare Corporation (~7.1% implied cap).
• NNN REIT (CIK 751364), Realty Income (CIK 726728), W. P. Carey (CIK 1025378), Agree Realty (CIK 917251), Essential Properties Realty Trust (CIK 1728951), VICI Properties (CIK 1705696) — Q1 2026 10-Qs and earnings 8-K exhibits/supplementals, used for the net-lease comparison: forward AFFO guidance, dividends, net debt/EBITDA(re), initial cash cap rates on Q1 investments (NNN 7.5%, Realty Income 7.1% blended, Agree 7.1%, Essential Properties 7.7% cash) and the loan/financing-receivable strip-out.
• Welltower (WELL), Ventas (VTR), American Healthcare REIT (AHR) — comparables for the large-cap healthcare and private-pay SHOP cohort.
• The Ensign Group (ENSG, CIK 1125376) — FY2025 10-K (filed 4 February 2026) and Q1 2026 disclosure, for tenant-side economics: Medicaid ~46.6% and Medicare ~24.7% of skilled-services revenue; record same-store occupancy 84.3%; skilled-mix days +9.6%; FY2026 EPS guidance $7.48–7.62; and the “Standard Bearer” captive-REIT segment (173 properties, 155 owned debt-free, $36.1M of Q1 2026 rental revenue at 2.7x coverage, leasing to 137 affiliated and 37 unaffiliated operators).
• PACS Group (PACS) — Q1 2026 results (11 May 2026: revenue $1.42bn +11.2%, net income $80.7M +184.2%, EPS $0.50); the 29 June 2026 agreement to acquire the operations of 34 facilities from Eduro Healthcare; the 27 April 2026 CFO transition; and the pending securities-fraud class action (class period 11 April – 16 December 2024).

4. Industry, transaction-market and factor data (third party)

• CBRE US Senior Housing & Care Investor Survey — 1H2014 (full cap-rate matrix; SNF Class A core 11.49%) and the 11th through 18th editions. 18th edition (April 2026 survey, 95% response rate): SNF Class A core 10.9% (−13bp), active adult 5.3%, independent living 5.9%, assisted living 6.5%, CCRC 7.9%, memory care 8.0%; 59% expect further compression, down from 84%; 19,839 seniors-housing units under construction (−6% y/y, sixteenth consecutive quarterly decline); market rents remain “well below levels that make new development feasible.” 17th edition (October 2025 survey): SNF core Class A 11.0%, Class B 12.1%, Class C 12.8%; non-core Class A 11.7%.
• Irving Levin Associates / LevinPro LTC — seniors housing and care M&A: 871 deals and $30.5bn disclosed in 2025 (records); Q1 2026 241 deals/$3.95bn and Q2 2026 240/$3.89bn; October 2025 a record 110 deals in one month. The Senior Care Acquisition Report, 30th and 31st editions: SNF average price per bed $97,700 (2023), $83,800 (2024), $105,600 (2025); assisted living $268,600 and independent living $263,600 in 2025. Critically, Levin’s 17 February 2026 release: “Skilled nursing deals were flat year over year despite higher spend, likely due to a shortage of sellers.”
• NIC and NIC MAP Vision — seniors-housing inventory growth 0.4% y/y in Q1 2026, the lowest on record back to 2006; ~1,500 units started in Q1 2025 (lowest since Q2 2009); ~60% of 140 tracked markets with zero active development; occupancy ~89.5% (nineteenth consecutive quarter of absorption exceeding inventory growth); ~1,368,300 US nursing-care beds; requirement of ~549,000 additional units by 2028 and ~806,000 by 2030. SNF-specific construction as a percentage of inventory is paywalled and is not asserted in this article; the sourced statements are that Q1 2026 was the first SNF inventory addition since 2017, that development is “near record lows,” that SNF occupancy passed 87% (highest since 2016) and that SNF rent growth exceeded 5% (fastest since 2008).
• Lument — “Skilled Nursing State of the Market” (13 March 2025): SNF median cap rate on H2 2024 closed transactions ~12%; owner-operators 75% of H2 2024 SNF buyers, real-estate firms and REITs ~21%; 221 closed SNF deals in 2024 (+36%). 2026 Outlook (20 February 2026): major healthcare REITs invested $25.28bn in 2025 versus $9.96bn in 2024.
• JLL, Marcus & Millichap, AHCA/NCAL — rolling four-quarter seniors-housing transaction volume ~$24bn (highest since 2015); 85–86% of surveyed investors intending to expand seniors-housing exposure in 2026; SNF construction cost $314–499 per square foot; the average US nursing home “around 40 to 50 years old.”
• Care REIT plc — Rule 2.7 announcement (Investegate RNS, 11 March 2025), the scheme of arrangement documents, the 17 April 2025 “Offer Update and No Increase Statement” (disclosing “an increased prominence of a relatively small number of anticipated dissenting shareholders”), and the FY2024 annual report (EPRA NTA 119.21p at 31 December 2024, portfolio revalued +4.3% to £679.0M). Third-party commentary: QuotedData (March 2025) — “the almost 10% discount to NAV this deal values the company feels like too much value is being left on the table”; Deutsche Numis — ~6.8% discount to book.
• AZI (azitrading.com) — daily price CSV for CTRE and the full comparable set (adjusted and unadjusted OHLC, dividends, splits, EMAs, beta, alpha), full history 29 May 2014 – 24 July 2026. Source for: close $43.25; all-time high $43.60 intraday (22 July 2026) and $43.40 closing (21 July); 52-week range $30.51–$43.60; total returns of +43.9% (1y), +133.6% (3y), +129.3% (5y, 18.1% annualised) and +555.8% since IPO; five-year maximum drawdown −30.6% (27 July 2021 to 29 April 2022); full-history maximum drawdown −67.4% (21 May 2019 to 18 March 2020); trailing one-year realised volatility 24.9%. Also the valuation_index own-history percentiles at 24 July 2026: price $43.25, TTM EPS $1.6117, BVPS $18.4483, P/B 2.34x at the 99.3rd percentile, P/S 19.3x at the 91.5th, composite 82.3rd, P/E 26.8x at the 56.2nd (discounted as unreliable for a REIT).
• FactorsToday (/api/stock-loadings, /leaderboard, /stock-info, /stock-specific-vol, /related-stocks, /factor-returns/historic) — ElasticNet factor loadings across four nested models (Momentum ~zero throughout; Quality negative throughout; Market +0.55, BetaFactor −0.36, InterestRate −0.35 in the all-factors model; R² 15–43%); specific volatility 18.89% against 24.89% total (~58% idiosyncratic); risk-adjusted track record by horizon (one-year Sharpe 1.69 on a −14.3% maximum drawdown; ten-year Sharpe 0.43 on a −67.4% drawdown); factor-similar peers (NNN 0.795, W. P. Carey 0.753, Healthcare Realty 0.750, Realty Income 0.745 — with Omega, Sabra, NHI and LTC absent); and the factor regime (Industry: REITs at a 252-day z-score of +3.84, the most in-favour of 121 factors; Healthcare Providers second at +3.01; InterestRate +5.12% over 21 days, z +1.91). Third-party statistical estimates, in-sample; reportable as facts about the model, not as primary data.
• ROIC.ai — company profile, income statement, balance sheet, cash flow, profitability/credit/liquidity ratios, enterprise value, valuation multiples and the news feed for CTRE and peers; and the transcript service. Used as a cross-check only for CareTrust’s revenue and EBITDA, whose definitions were rejected: ROIC classifies CareTrust’s interest income as non-operating, understating FY2025 revenue by 22.5% and TTM EBITDA by ~24.9% and inflating EV/TTM EBITDA to 26.1x against a correct ~19.6x. ROIC’s dvd_payout_ratio, return_on_inv_capital and book_val_per_sh for CareTrust are also unusable and are not cited.

5. Comparable-company and framework sources

• Peer healthcare and net-lease REIT filings — the Q1 2026 Forms 10-Q, FY2025 Forms 10-K, earnings releases and supplementals of Omega Healthcare, Sabra Health Care, National Health Investors, LTC Properties, Strawberry Fields REIT, Welltower, Ventas, American Healthcare REIT, Healthpeak, NNN REIT, Realty Income, W. P. Carey, Agree Realty, Essential Properties Realty Trust and VICI Properties, together with their Q1 2026 earnings calls, all retrieved from SEC EDGAR and company investor-relations sites. These are the basis for the multiple, cap-rate, leverage and credit-history comparisons in Sections 4, 5, 9 and 10.
• The Ensign Group — FY2025 Form 10-K (filed 4 February 2026), Q1 2026 results and earnings call, for tenant-side payor mix, occupancy, coverage and the Standard Bearer captive-REIT segment.
• Short-seller research on The Ensign Group — Hunterbrook Media, 8 June 2026, alleging a “deliberate understaffing scheme”; Muddy Waters Research, 11 June 2026. Both are third-party advocacy documents, unadjudicated, and are treated in this article as allegations rather than findings. Ensign’s public rebuttal (85% of operations at four- or five-star quality measures; same-store survey outperformance of 22% versus state and 31% versus county averages; director-of-nursing turnover down 32% over two years) is given alongside.
• Care REIT plc — the Rule 2.7 announcement (11 March 2025), scheme of arrangement documents, the 17 April 2025 “Offer Update and No Increase Statement,” and the FY2024 annual report, all published via the London regulatory news service. Third-party commentary from QuotedData and Deutsche Numis.
• Analytical frameworks — the competitive-advantage taxonomy applied in Section 4 follows Bruce Greenwald and Judd Kahn, Competition Demystified (supply/cost advantage, demand-side customer captivity, economies of scale plus captivity). The supply-side capital-cycle reading in Sections 3 and 5 follows Edward Chancellor (ed.), Capital Returns: Investing Through the Capital Cycle (Marathon Asset Management) — high returns attract capital, capital competes returns away, and the durability of a return depends on whether the supply side can respond.
• Public healthcare-policy sources — CMS payment rules and the FY2027 SNF prospective-payment proposal; the One Big Beautiful Bill Act (enacted 4 July 2025) provider-tax and state-directed-payment provisions; the CMS Managed Care Final Rule (22 April 2024); Congressional Budget Office coverage estimates; and Congressional Research Service report R40834 (8 April 2010) for the statutory Medicare/Medicaid design split and the history of certificate-of-need regulation. Hospital-sector disclosures (notably Universal Health Services) were used for the dated Medicaid supplemental-payment calendar and for the empirical observation that one large operator’s disclosed net supplemental benefit rose in the twelve months after the 2025 law was enacted.

6. Stated limitations

1. Some secondary corroboration was unavailable. The PACS Group recovery and parts of the skilled-nursing transaction-market read rest on company press releases and filings rather than on independent trade-press verification. No conclusion in this article depends on a secondary source alone.
2. SNF-specific construction as a percentage of inventory is paywalled (NIC MAP Vision) and is not asserted anywhere in this article.
3. CareTrust’s EBITDAR/EBITDARM coverage ratios appear in no filed document — only in furnished Item 7.01 supplementals and on calls. The reporting lag cannot be established from EDGAR, and every coverage-based conclusion inherits that limitation.
4. FY2019–FY2022 normalized EBITDA is not published; Normalized FFO plus interest expense was used as a proxy for the cash-return-on-invested-capital series. The direction (8.65% → 9.33%) is robust; individual early-year points are approximations.
5. The pro-forma share count (~235M) and net debt (~$830M) used throughout Section 10 are estimates reconciled to the Q1 2026 10-Q cover, the guidance share count and the May 2026 forward; the fully-settled count is nearer 250–260M. Every multiple moves with this and the assumption is stated in-line.
6. The 1.0–1.2x book comparable multiple for the loan book is an assumption. The direction of the conclusion is robust; the ~$6–7 per share magnitude is an estimate.